<?xml version="1.0" encoding="GB2312"?>
<?xml-stylesheet type="text/xsl" href="/blog/oblogstyle/rss.xsl"?>
<rss version="2.0">
<channel>
<title><![CDATA[天津华裕生物科技有限公司]]></title>
<link>http://www.clinet.com.cn/blogu/109/index.html</link>
<description><![CDATA[天津华裕生物科技有限公司]]></description>
<item>
<title><![CDATA[CA125 阴性卵巢癌病人血清HE4 水平]]></title>
<link>http://www.clinet.com.cn/blogu/109/archives/2010/4801.html</link>
<description><![CDATA[<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-SIZE: 12pt"><B><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>CA125 (-) </SPAN></B><B><SPAN style="FONT-FAMILY: 宋体; mso-bidi-font-size: 10.5pt; mso-ascii-font-family: Arial; mso-bidi-font-family: Arial">卵巢癌病人血清</SPAN></B><B><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US> HE4 </SPAN></B><B><SPAN style="FONT-FAMILY: 宋体; mso-bidi-font-size: 10.5pt; mso-ascii-font-family: Arial; mso-bidi-font-family: Arial">水平</SPAN></B><B><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US><?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></B></SPAN></P>
<TABLE style="WIDTH: 370.5pt; mso-cellspacing: 0cm; mso-padding-alt: 0cm 0cm 0cm 0cm" class=MsoNormalTable border=0 cellSpacing=0 cellPadding=0 width=494>
<TBODY>
<TR style="HEIGHT: 15.75pt; mso-yfti-irow: 0; mso-yfti-firstrow: yes">
<TD style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: black 1.5pt solid; PADDING-BOTTOM: 0cm; PADDING-LEFT: 0cm; WIDTH: 151.5pt; PADDING-RIGHT: 0cm; BACKGROUND: white; HEIGHT: 15.75pt; BORDER-TOP: black 1.5pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-top-alt: solid black 1.5pt; mso-border-left-alt: solid black 1.5pt; mso-border-right-alt: solid black .75pt" rowSpan=2 width=202>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: 宋体; mso-bidi-font-size: 10.5pt; mso-ascii-font-family: Arial; mso-bidi-font-family: Arial; mso-bidi-font-weight: bold">肿瘤标志物组合</SPAN><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US><o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; PADDING-LEFT: 0cm; WIDTH: 219.75pt; PADDING-RIGHT: 0cm; BACKGROUND: white; HEIGHT: 15.75pt; BORDER-TOP: black 1.5pt solid; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0cm; mso-border-top-alt: solid black 1.5pt; mso-border-left-alt: solid black .75pt; mso-border-bottom-alt: solid black .75pt" width=293 colSpan=2>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: 宋体; mso-bidi-font-size: 10.5pt; mso-ascii-font-family: Arial; mso-bidi-font-family: Arial; mso-bidi-font-weight: bold">卵巢癌病人</SPAN><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt; mso-bidi-font-weight: bold" lang=EN-US>(n=76)</SPAN><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US><o:p></o:p></SPAN></P></TD></TR>
<TR style="HEIGHT: 36pt; mso-yfti-irow: 1">
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; PADDING-LEFT: 0cm; WIDTH: 98.25pt; PADDING-RIGHT: 0cm; BACKGROUND: white; HEIGHT: 36pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .75pt" width=131>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt; mso-bidi-font-weight: bold" lang=EN-US>(n)</SPAN><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US><o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; PADDING-LEFT: 0cm; WIDTH: 122.25pt; PADDING-RIGHT: 0cm; BACKGROUND: white; HEIGHT: 36pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1.5pt solid; PADDING-TOP: 0cm; mso-border-right-alt: solid black 1.5pt; mso-border-alt: solid black .75pt" width=163>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt; mso-bidi-font-weight: bold" lang=EN-US>% of patient</SPAN><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US><o:p></o:p></SPAN></P></TD></TR>
<TR style="HEIGHT: 36pt; mso-yfti-irow: 2">
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1.5pt solid; PADDING-BOTTOM: 0cm; PADDING-LEFT: 0cm; WIDTH: 151.5pt; PADDING-RIGHT: 0cm; BACKGROUND: white; HEIGHT: 36pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-left-alt: solid black 1.5pt; mso-border-alt: solid black .75pt" width=202>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt; mso-bidi-font-weight: bold" lang=EN-US>CA125(↑)</SPAN><SPAN style="FONT-FAMILY: 宋体; mso-bidi-font-size: 10.5pt; mso-ascii-font-family: Arial; mso-bidi-font-family: Arial; mso-bidi-font-weight: bold">，</SPAN><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt; mso-bidi-font-weight: bold" lang=EN-US>HE4(↑)</SPAN><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US><o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; PADDING-LEFT: 0cm; WIDTH: 98.25pt; PADDING-RIGHT: 0cm; BACKGROUND: white; HEIGHT: 36pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .75pt" width=131>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt; mso-bidi-font-weight: bold" lang=EN-US>58</SPAN><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US><o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; PADDING-LEFT: 0cm; WIDTH: 122.25pt; PADDING-RIGHT: 0cm; BACKGROUND: white; HEIGHT: 36pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1.5pt solid; PADDING-TOP: 0cm; mso-border-right-alt: solid black 1.5pt; mso-border-alt: solid black .75pt" width=163>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt; mso-bidi-font-weight: bold" lang=EN-US>76%</SPAN><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US><o:p></o:p></SPAN></P></TD></TR>
<TR style="HEIGHT: 36pt; mso-yfti-irow: 3">
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1.5pt solid; PADDING-BOTTOM: 0cm; PADDING-LEFT: 0cm; WIDTH: 151.5pt; PADDING-RIGHT: 0cm; BACKGROUND: #00e4a8; HEIGHT: 36pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-left-alt: solid black 1.5pt; mso-border-alt: solid black .75pt" width=202>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt; mso-bidi-font-weight: bold" lang=EN-US>CA125(-)</SPAN><SPAN style="FONT-FAMILY: 宋体; mso-bidi-font-size: 10.5pt; mso-ascii-font-family: Arial; mso-bidi-font-family: Arial; mso-bidi-font-weight: bold">，</SPAN><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt; mso-bidi-font-weight: bold" lang=EN-US> HE4(↑)</SPAN><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US><o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; PADDING-LEFT: 0cm; WIDTH: 98.25pt; PADDING-RIGHT: 0cm; BACKGROUND: #00e4a8; HEIGHT: 36pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .75pt" width=131>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt; mso-bidi-font-weight: bold" lang=EN-US>13</SPAN><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US><o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; PADDING-LEFT: 0cm; WIDTH: 122.25pt; PADDING-RIGHT: 0cm; BACKGROUND: #00e4a8; HEIGHT: 36pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1.5pt solid; PADDING-TOP: 0cm; mso-border-right-alt: solid black 1.5pt; mso-border-alt: solid black .75pt" width=163>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt; mso-bidi-font-weight: bold" lang=EN-US>17%</SPAN><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US><o:p></o:p></SPAN></P></TD></TR>
<TR style="HEIGHT: 36pt; mso-yfti-irow: 4">
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1.5pt solid; PADDING-BOTTOM: 0cm; PADDING-LEFT: 0cm; WIDTH: 151.5pt; PADDING-RIGHT: 0cm; BACKGROUND: white; HEIGHT: 36pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-left-alt: solid black 1.5pt; mso-border-alt: solid black .75pt" width=202>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt; mso-bidi-font-weight: bold" lang=EN-US>CA125(↑)</SPAN><SPAN style="FONT-FAMILY: 宋体; mso-bidi-font-size: 10.5pt; mso-ascii-font-family: Arial; mso-bidi-font-family: Arial; mso-bidi-font-weight: bold">，</SPAN><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt; mso-bidi-font-weight: bold" lang=EN-US> HE4(-)</SPAN><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US><o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; PADDING-LEFT: 0cm; WIDTH: 98.25pt; PADDING-RIGHT: 0cm; BACKGROUND: white; HEIGHT: 36pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .75pt" width=131>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt; mso-bidi-font-weight: bold" lang=EN-US>2</SPAN><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US><o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; PADDING-LEFT: 0cm; WIDTH: 122.25pt; PADDING-RIGHT: 0cm; BACKGROUND: white; HEIGHT: 36pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1.5pt solid; PADDING-TOP: 0cm; mso-border-right-alt: solid black 1.5pt; mso-border-alt: solid black .75pt" width=163>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt; mso-bidi-font-weight: bold" lang=EN-US>3%</SPAN><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US><o:p></o:p></SPAN></P></TD></TR>
<TR style="HEIGHT: 36pt; mso-yfti-irow: 5; mso-yfti-lastrow: yes">
<TD style="BORDER-BOTTOM: black 1.5pt solid; BORDER-LEFT: black 1.5pt solid; PADDING-BOTTOM: 0cm; PADDING-LEFT: 0cm; WIDTH: 151.5pt; PADDING-RIGHT: 0cm; BACKGROUND: white; HEIGHT: 36pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-top-alt: .75pt; mso-border-left-alt: 1.5pt; mso-border-right-alt: .75pt; mso-border-bottom-alt: 1.5pt; mso-border-color-alt: black; mso-border-style-alt: solid" width=202>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt; mso-bidi-font-weight: bold" lang=EN-US>CA125(-)</SPAN><SPAN style="FONT-FAMILY: 宋体; mso-bidi-font-size: 10.5pt; mso-ascii-font-family: Arial; mso-bidi-font-family: Arial; mso-bidi-font-weight: bold">，</SPAN><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt; mso-bidi-font-weight: bold" lang=EN-US> HE4(-)</SPAN><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US><o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1.5pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; PADDING-LEFT: 0cm; WIDTH: 98.25pt; PADDING-RIGHT: 0cm; BACKGROUND: white; HEIGHT: 36pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-bottom-alt: solid black 1.5pt; mso-border-alt: solid black .75pt" width=131>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt; mso-bidi-font-weight: bold" lang=EN-US>3</SPAN><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US><o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1.5pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; PADDING-LEFT: 0cm; WIDTH: 122.25pt; PADDING-RIGHT: 0cm; BACKGROUND: white; HEIGHT: 36pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1.5pt solid; PADDING-TOP: 0cm; mso-border-top-alt: .75pt; mso-border-left-alt: .75pt; mso-border-right-alt: 1.5pt; mso-border-bottom-alt: 1.5pt; mso-border-color-alt: black; mso-border-style-alt: solid" width=163>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt; mso-bidi-font-weight: bold" lang=EN-US>4%</SPAN><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US><o:p></o:p></SPAN></P></TD></TR></TBODY></TABLE>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US><o:p><SPAN style="FONT-SIZE: 12pt">&nbsp;</SPAN></o:p></SPAN></P>]]></description>
<author>华裕</author>
<pubDate>2010-7-30 14:58:00</pubDate>
</item>
<item>
<title><![CDATA[血清HE4 检测I 期卵巢癌的灵敏度]]></title>
<link>http://www.clinet.com.cn/blogu/109/archives/2010/4793.html</link>
<description><![CDATA[<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-SIZE: 12pt"><B><SPAN style="FONT-FAMILY: 宋体; mso-bidi-font-size: 10.5pt; mso-ascii-font-family: Arial; mso-bidi-font-family: Arial"></SPAN></B><B><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US><?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></B></SPAN>&nbsp;</P>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-SIZE: 12pt"><SPAN style="FONT-FAMILY: 宋体; mso-bidi-font-size: 10.5pt; mso-ascii-font-family: Arial; mso-bidi-font-family: Arial; mso-bidi-font-weight: bold">（</SPAN><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt; mso-bidi-font-weight: bold" lang=EN-US>% N=144) </SPAN><SPAN style="FONT-FAMILY: 宋体; mso-bidi-font-size: 10.5pt; mso-ascii-font-family: Arial; mso-bidi-font-family: Arial; mso-bidi-font-weight: bold">（对照为良性疾病）</SPAN><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US><o:p></o:p></SPAN></SPAN></P>
<TABLE style="WIDTH: 383.25pt; mso-cellspacing: 0cm; mso-padding-alt: 0cm 0cm 0cm 0cm" class=MsoNormalTable border=0 cellSpacing=0 cellPadding=0 width=511>
<TBODY>
<TR style="HEIGHT: 32.25pt; mso-yfti-irow: 0; mso-yfti-firstrow: yes">
<TD style="BORDER-BOTTOM: black 1.5pt solid; BORDER-LEFT: black 1.5pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 125.25pt; PADDING-RIGHT: 0cm; HEIGHT: 32.25pt; BORDER-TOP: black 1.5pt solid; BORDER-RIGHT: black 1.5pt solid; PADDING-TOP: 0cm" width=167>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: 宋体; mso-bidi-font-size: 10.5pt; mso-ascii-font-family: Arial; mso-bidi-font-family: Arial">标志物组合</SPAN><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US><o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1.5pt solid; BORDER-LEFT: black 1.5pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 68.25pt; PADDING-RIGHT: 0cm; HEIGHT: 32.25pt; BORDER-TOP: black 1.5pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black 1.5pt; mso-border-right-alt: solid black .75pt" vAlign=bottom width=91>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>ROC-AUC<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1.5pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 66.75pt; PADDING-RIGHT: 0cm; HEIGHT: 32.25pt; BORDER-TOP: black 1.5pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-right-alt: .75pt; mso-border-top-alt: 1.5pt; mso-border-left-alt: .75pt; mso-border-bottom-alt: 1.5pt; mso-border-color-alt: black; mso-border-style-alt: solid" vAlign=bottom width=89>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>90% <o:p></o:p></SPAN></P>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>Specificity<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1.5pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 63.75pt; PADDING-RIGHT: 0cm; HEIGHT: 32.25pt; BORDER-TOP: black 1.5pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-right-alt: .75pt; mso-border-top-alt: 1.5pt; mso-border-left-alt: .75pt; mso-border-bottom-alt: 1.5pt; mso-border-color-alt: black; mso-border-style-alt: solid" vAlign=bottom width=85>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>95% <o:p></o:p></SPAN></P>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>Specificity<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1.5pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 60.75pt; PADDING-RIGHT: 0cm; HEIGHT: 32.25pt; BORDER-TOP: black 1.5pt solid; BORDER-RIGHT: black 1.5pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black 1.5pt; mso-border-left-alt: solid black .75pt" vAlign=bottom width=81>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>98% <o:p></o:p></SPAN></P>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>Specificity<o:p></o:p></SPAN></P></TD></TR>
<TR style="HEIGHT: 15.75pt; mso-yfti-irow: 1">
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1.5pt solid; PADDING-BOTTOM: 0cm; PADDING-LEFT: 0cm; WIDTH: 125.25pt; PADDING-RIGHT: 0cm; BACKGROUND: yellow; HEIGHT: 15.75pt; BORDER-TOP: black 1.5pt solid; BORDER-RIGHT: black 1.5pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black 1.5pt; mso-border-bottom-alt: solid black .75pt" vAlign=bottom width=167>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>CA125<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1.5pt solid; PADDING-BOTTOM: 0cm; PADDING-LEFT: 0cm; WIDTH: 68.25pt; PADDING-RIGHT: 0cm; BACKGROUND: yellow; HEIGHT: 15.75pt; BORDER-TOP: black 1.5pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-right-alt: .75pt; mso-border-top-alt: 1.5pt; mso-border-left-alt: 1.5pt; mso-border-bottom-alt: .75pt; mso-border-color-alt: black; mso-border-style-alt: solid" vAlign=bottom width=91>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>68<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; PADDING-LEFT: 0cm; WIDTH: 66.75pt; PADDING-RIGHT: 0cm; BACKGROUND: yellow; HEIGHT: 15.75pt; BORDER-TOP: black 1.5pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .75pt; mso-border-top-alt: solid black 1.5pt" vAlign=bottom width=89>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>20<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; PADDING-LEFT: 0cm; WIDTH: 63.75pt; PADDING-RIGHT: 0cm; BACKGROUND: yellow; HEIGHT: 15.75pt; BORDER-TOP: black 1.5pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .75pt; mso-border-top-alt: solid black 1.5pt" vAlign=bottom width=85>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>8<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; PADDING-LEFT: 0cm; WIDTH: 60.75pt; PADDING-RIGHT: 0cm; BACKGROUND: yellow; HEIGHT: 15.75pt; BORDER-TOP: black 1.5pt solid; BORDER-RIGHT: black 1.5pt solid; PADDING-TOP: 0cm; mso-border-right-alt: 1.5pt; mso-border-top-alt: 1.5pt; mso-border-left-alt: .75pt; mso-border-bottom-alt: .75pt; mso-border-color-alt: black; mso-border-style-alt: solid" vAlign=bottom width=81>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>7<o:p></o:p></SPAN></P></TD></TR>
<TR style="HEIGHT: 15.75pt; mso-yfti-irow: 2">
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1.5pt solid; PADDING-BOTTOM: 0cm; PADDING-LEFT: 0cm; WIDTH: 125.25pt; PADDING-RIGHT: 0cm; BACKGROUND: #ff7c80; HEIGHT: 15.75pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1.5pt solid; PADDING-TOP: 0cm; mso-border-right-alt: 1.5pt; mso-border-top-alt: .75pt; mso-border-left-alt: 1.5pt; mso-border-bottom-alt: .75pt; mso-border-color-alt: black; mso-border-style-alt: solid" vAlign=bottom width=167>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>HE4<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1.5pt solid; PADDING-BOTTOM: 0cm; PADDING-LEFT: 0cm; WIDTH: 68.25pt; PADDING-RIGHT: 0cm; BACKGROUND: #ff7c80; HEIGHT: 15.75pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .75pt; mso-border-left-alt: solid black 1.5pt" vAlign=bottom width=91>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>78<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; PADDING-LEFT: 0cm; WIDTH: 66.75pt; PADDING-RIGHT: 0cm; BACKGROUND: #ff7c80; HEIGHT: 15.75pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .75pt" vAlign=bottom width=89>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>50<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; PADDING-LEFT: 0cm; WIDTH: 63.75pt; PADDING-RIGHT: 0cm; BACKGROUND: #ff7c80; HEIGHT: 15.75pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .75pt" vAlign=bottom width=85>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>49<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; PADDING-LEFT: 0cm; WIDTH: 60.75pt; PADDING-RIGHT: 0cm; BACKGROUND: #ff7c80; HEIGHT: 15.75pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1.5pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .75pt; mso-border-right-alt: solid black 1.5pt" vAlign=bottom width=81>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>29<o:p></o:p></SPAN></P></TD></TR>
<TR style="HEIGHT: 15.75pt; mso-yfti-irow: 3">
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1.5pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 125.25pt; PADDING-RIGHT: 0cm; HEIGHT: 15.75pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1.5pt solid; PADDING-TOP: 0cm; mso-border-right-alt: 1.5pt; mso-border-top-alt: .75pt; mso-border-left-alt: 1.5pt; mso-border-bottom-alt: .75pt; mso-border-color-alt: black; mso-border-style-alt: solid" vAlign=bottom width=167>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>SMRP<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1.5pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 68.25pt; PADDING-RIGHT: 0cm; HEIGHT: 15.75pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .75pt; mso-border-left-alt: solid black 1.5pt" vAlign=bottom width=91>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>66<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 66.75pt; PADDING-RIGHT: 0cm; HEIGHT: 15.75pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .75pt" vAlign=bottom width=89>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>29<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 63.75pt; PADDING-RIGHT: 0cm; HEIGHT: 15.75pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .75pt" vAlign=bottom width=85>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>29<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 60.75pt; PADDING-RIGHT: 0cm; HEIGHT: 15.75pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1.5pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .75pt; mso-border-right-alt: solid black 1.5pt" vAlign=bottom width=81>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>14<o:p></o:p></SPAN></P></TD></TR>
<TR style="HEIGHT: 15.75pt; mso-yfti-irow: 4">
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1.5pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 125.25pt; PADDING-RIGHT: 0cm; HEIGHT: 15.75pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1.5pt solid; PADDING-TOP: 0cm; mso-border-right-alt: 1.5pt; mso-border-top-alt: .75pt; mso-border-left-alt: 1.5pt; mso-border-bottom-alt: .75pt; mso-border-color-alt: black; mso-border-style-alt: solid" vAlign=bottom width=167>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>CA72-4<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1.5pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 68.25pt; PADDING-RIGHT: 0cm; HEIGHT: 15.75pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .75pt; mso-border-left-alt: solid black 1.5pt" vAlign=bottom width=91>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>75<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 66.75pt; PADDING-RIGHT: 0cm; HEIGHT: 15.75pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .75pt" vAlign=bottom width=89>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>35<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 63.75pt; PADDING-RIGHT: 0cm; HEIGHT: 15.75pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .75pt" vAlign=bottom width=85>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>35<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 60.75pt; PADDING-RIGHT: 0cm; HEIGHT: 15.75pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1.5pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .75pt; mso-border-right-alt: solid black 1.5pt" vAlign=bottom width=81>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>21<o:p></o:p></SPAN></P></TD></TR>
<TR style="HEIGHT: 15.75pt; mso-yfti-irow: 5">
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1.5pt solid; PADDING-BOTTOM: 0cm; PADDING-LEFT: 0cm; WIDTH: 125.25pt; PADDING-RIGHT: 0cm; BACKGROUND: #ffcc66; HEIGHT: 15.75pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1.5pt solid; PADDING-TOP: 0cm; mso-border-right-alt: 1.5pt; mso-border-top-alt: .75pt; mso-border-left-alt: 1.5pt; mso-border-bottom-alt: .75pt; mso-border-color-alt: black; mso-border-style-alt: solid" vAlign=bottom width=167>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>CA125 + HE4<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1.5pt solid; PADDING-BOTTOM: 0cm; PADDING-LEFT: 0cm; WIDTH: 68.25pt; PADDING-RIGHT: 0cm; BACKGROUND: #ffcc66; HEIGHT: 15.75pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .75pt; mso-border-left-alt: solid black 1.5pt" vAlign=bottom width=91>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>77<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; PADDING-LEFT: 0cm; WIDTH: 66.75pt; PADDING-RIGHT: 0cm; BACKGROUND: #ffcc66; HEIGHT: 15.75pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .75pt" vAlign=bottom width=89>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>50<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; PADDING-LEFT: 0cm; WIDTH: 63.75pt; PADDING-RIGHT: 0cm; BACKGROUND: #ffcc66; HEIGHT: 15.75pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .75pt" vAlign=bottom width=85>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>43<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; PADDING-LEFT: 0cm; WIDTH: 60.75pt; PADDING-RIGHT: 0cm; BACKGROUND: #ffcc66; HEIGHT: 15.75pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1.5pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .75pt; mso-border-right-alt: solid black 1.5pt" vAlign=bottom width=81>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>36<o:p></o:p></SPAN></P></TD></TR>
<TR style="HEIGHT: 15.75pt; mso-yfti-irow: 6">
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1.5pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 125.25pt; PADDING-RIGHT: 0cm; HEIGHT: 15.75pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1.5pt solid; PADDING-TOP: 0cm; mso-border-right-alt: 1.5pt; mso-border-top-alt: .75pt; mso-border-left-alt: 1.5pt; mso-border-bottom-alt: .75pt; mso-border-color-alt: black; mso-border-style-alt: solid" vAlign=bottom width=167>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>CA125 + SMRP<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1.5pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 68.25pt; PADDING-RIGHT: 0cm; HEIGHT: 15.75pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .75pt; mso-border-left-alt: solid black 1.5pt" vAlign=bottom width=91>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>73<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 66.75pt; PADDING-RIGHT: 0cm; HEIGHT: 15.75pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .75pt" vAlign=bottom width=89>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>36<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 63.75pt; PADDING-RIGHT: 0cm; HEIGHT: 15.75pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .75pt" vAlign=bottom width=85>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>29<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 60.75pt; PADDING-RIGHT: 0cm; HEIGHT: 15.75pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1.5pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .75pt; mso-border-right-alt: solid black 1.5pt" vAlign=bottom width=81>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>21<o:p></o:p></SPAN></P></TD></TR>
<TR style="HEIGHT: 15.75pt; mso-yfti-irow: 7">
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1.5pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 125.25pt; PADDING-RIGHT: 0cm; HEIGHT: 15.75pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1.5pt solid; PADDING-TOP: 0cm; mso-border-right-alt: 1.5pt; mso-border-top-alt: .75pt; mso-border-left-alt: 1.5pt; mso-border-bottom-alt: .75pt; mso-border-color-alt: black; mso-border-style-alt: solid" vAlign=bottom width=167>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>CA125 + CA72-4<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1.5pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 68.25pt; PADDING-RIGHT: 0cm; HEIGHT: 15.75pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .75pt; mso-border-left-alt: solid black 1.5pt" vAlign=bottom width=91>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>71<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 66.75pt; PADDING-RIGHT: 0cm; HEIGHT: 15.75pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .75pt" vAlign=bottom width=89>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>28<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 63.75pt; PADDING-RIGHT: 0cm; HEIGHT: 15.75pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .75pt" vAlign=bottom width=85>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>21<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 60.75pt; PADDING-RIGHT: 0cm; HEIGHT: 15.75pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1.5pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .75pt; mso-border-right-alt: solid black 1.5pt" vAlign=bottom width=81>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>21<o:p></o:p></SPAN></P></TD></TR>
<TR style="HEIGHT: 16.5pt; mso-yfti-irow: 8">
<TD style="BORDER-BOTTOM: black 1.5pt solid; BORDER-LEFT: black 1.5pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 125.25pt; PADDING-RIGHT: 0cm; HEIGHT: 16.5pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1.5pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black 1.5pt; mso-border-top-alt: solid black .75pt" vAlign=bottom width=167>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>CA125 + HE4 + CA72-4<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1.5pt solid; BORDER-LEFT: black 1.5pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 68.25pt; PADDING-RIGHT: 0cm; HEIGHT: 16.5pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-right-alt: .75pt; mso-border-top-alt: .75pt; mso-border-left-alt: 1.5pt; mso-border-bottom-alt: 1.5pt; mso-border-color-alt: black; mso-border-style-alt: solid" vAlign=bottom width=91>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>77<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1.5pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 66.75pt; PADDING-RIGHT: 0cm; HEIGHT: 16.5pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .75pt; mso-border-bottom-alt: solid black 1.5pt" vAlign=bottom width=89>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>50<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1.5pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 63.75pt; PADDING-RIGHT: 0cm; HEIGHT: 16.5pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .75pt; mso-border-bottom-alt: solid black 1.5pt" vAlign=bottom width=85>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>36<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1.5pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 60.75pt; PADDING-RIGHT: 0cm; HEIGHT: 16.5pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1.5pt solid; PADDING-TOP: 0cm; mso-border-right-alt: 1.5pt; mso-border-top-alt: .75pt; mso-border-left-alt: .75pt; mso-border-bottom-alt: 1.5pt; mso-border-color-alt: black; mso-border-style-alt: solid" vAlign=bottom width=81>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>35<o:p></o:p></SPAN></P></TD></TR>
<TR style="HEIGHT: 27pt; mso-yfti-irow: 9; mso-yfti-lastrow: yes">
<TD style="BORDER-BOTTOM: black 1.5pt solid; BORDER-LEFT: black 1.5pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 125.25pt; PADDING-RIGHT: 0cm; HEIGHT: 27pt; BORDER-TOP: black 1.5pt solid; BORDER-RIGHT: black 1.5pt solid; PADDING-TOP: 0cm" vAlign=bottom width=167>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>CA125 + HE4 +SMRP + CA72-4<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1.5pt solid; BORDER-LEFT: black 1.5pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 68.25pt; PADDING-RIGHT: 0cm; HEIGHT: 27pt; BORDER-TOP: black 1.5pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black 1.5pt; mso-border-right-alt: solid black .75pt" vAlign=bottom width=91>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>77<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1.5pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 66.75pt; PADDING-RIGHT: 0cm; HEIGHT: 27pt; BORDER-TOP: black 1.5pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-right-alt: .75pt; mso-border-top-alt: 1.5pt; mso-border-left-alt: .75pt; mso-border-bottom-alt: 1.5pt; mso-border-color-alt: black; mso-border-style-alt: solid" vAlign=bottom width=89>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>51<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1.5pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 63.75pt; PADDING-RIGHT: 0cm; HEIGHT: 27pt; BORDER-TOP: black 1.5pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-right-alt: .75pt; mso-border-top-alt: 1.5pt; mso-border-left-alt: .75pt; mso-border-bottom-alt: 1.5pt; mso-border-color-alt: black; mso-border-style-alt: solid" vAlign=bottom width=85>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>36<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1.5pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 60.75pt; PADDING-RIGHT: 0cm; HEIGHT: 27pt; BORDER-TOP: black 1.5pt solid; BORDER-RIGHT: black 1.5pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black 1.5pt; mso-border-left-alt: solid black .75pt" vAlign=bottom width=81>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>36<o:p></o:p></SPAN></P></TD></TR></TBODY></TABLE>]]></description>
<author>华裕</author>
<pubDate>2010-7-29 8:53:00</pubDate>
</item>
<item>
<title><![CDATA[游记——夏日的海滩]]></title>
<link>http://www.clinet.com.cn/blogu/109/archives/2010/4750.html</link>
<description><![CDATA[<P style="TEXT-ALIGN: left; MARGIN: 0cm 0cm 0pt; mso-pagination: widow-orphan" class=MsoNormal align=left><SPAN style="COLOR: #000080; FONT-SIZE: 12pt"><SPAN style="FONT-FAMILY: 宋体; COLOR: #000080; mso-bidi-font-family: 宋体; mso-font-kerning: 0pt; mso-bidi-font-size: 10.5pt">&nbsp;&nbsp;&nbsp;&nbsp; 炎炎夏日，令人对海边的向往比以往更加深刻。</SPAN><SPAN style="FONT-FAMILY: 宋体; COLOR: #000080; mso-bidi-font-size: 10.5pt">于是我们迫不及待的去了美丽的北戴河。周五下班后，我们</SPAN><SPAN style="FONT-FAMILY: 宋体; COLOR: #000080; mso-bidi-font-family: 宋体; mso-font-kerning: 0pt; mso-bidi-font-size: 10.5pt">在一路欢声笑语中来到了这个美丽的海滨小城。</SPAN></SPAN></P>
<P style="TEXT-ALIGN: left; MARGIN: 0cm 0cm 0pt; mso-pagination: widow-orphan" class=MsoNormal align=left><SPAN style="COLOR: #000080; FONT-SIZE: 12pt"><SPAN style="FONT-FAMILY: 宋体; COLOR: #000080; mso-bidi-font-family: 宋体; mso-font-kerning: 0pt; mso-bidi-font-size: 10.5pt"><SPAN style="COLOR: #000080" lang=EN-US><?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></SPAN></SPAN>&nbsp;</P>
<P style="TEXT-ALIGN: left; MARGIN: 0cm 0cm 0pt; mso-pagination: widow-orphan" class=MsoNormal align=left><SPAN style="COLOR: #000080; FONT-SIZE: 12pt"><SPAN style="FONT-FAMILY: 宋体; COLOR: #000080; mso-bidi-font-family: 宋体; mso-font-kerning: 0pt; mso-bidi-font-size: 10.5pt" lang=EN-US>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</SPAN><SPAN style="FONT-FAMILY: 宋体; COLOR: #000080; mso-bidi-font-size: 10.5pt">空气里弥漫着海水那微微的咸味儿，似乎一伸手就可触及海水，一张嘴就可以吃到海鲜。</SPAN><SPAN style="FONT-FAMILY: 宋体; COLOR: #000080; mso-bidi-font-family: 宋体; mso-font-kerning: 0pt; mso-bidi-font-size: 10.5pt">到了这里，怎么少得了吃海鲜呢，安放好行李放，我们就来到了附近的海鲜馆，面前是海水涟涟，耳边是海浪滔滔，嘴里还咀嚼着美味，神仙也会羡慕吧。</SPAN></SPAN></P>
<P style="TEXT-ALIGN: left; MARGIN: 0cm 0cm 0pt; mso-pagination: widow-orphan" class=MsoNormal align=left><SPAN style="COLOR: #000080; FONT-SIZE: 12pt"><SPAN style="FONT-FAMILY: 宋体; COLOR: #000080; mso-bidi-font-family: 宋体; mso-font-kerning: 0pt; mso-bidi-font-size: 10.5pt"><SPAN style="COLOR: #000080" lang=EN-US><o:p></o:p></SPAN></SPAN></SPAN>&nbsp;</P>
<P style="TEXT-ALIGN: left; TEXT-INDENT: 31.5pt; MARGIN: 0cm 0cm 0pt; mso-pagination: widow-orphan; mso-char-indent-count: 3.0" class=MsoNormal align=left><SPAN style="FONT-FAMILY: 宋体; COLOR: #000080; FONT-SIZE: 12pt; mso-bidi-font-family: 宋体; mso-font-kerning: 0pt; mso-bidi-font-size: 10.5pt">美美的睡了一觉之后，一大早，我们就去了海滨浴场去与大海做亲密接触了。放眼看沧海，水天一色，海浪击石，岂是一个美字了得！进入到水里仿佛自己也化身成鱼，凉爽，惬意，洗去这夏日的燥热。</SPAN></P>
<P style="TEXT-ALIGN: left; TEXT-INDENT: 31.5pt; MARGIN: 0cm 0cm 0pt; mso-pagination: widow-orphan; mso-char-indent-count: 3.0" class=MsoNormal align=left><SPAN style="FONT-FAMILY: 宋体; COLOR: #000080; FONT-SIZE: 12pt; mso-bidi-font-family: 宋体; mso-font-kerning: 0pt; mso-bidi-font-size: 10.5pt"><SPAN style="COLOR: #000080" lang=EN-US><o:p></o:p></SPAN></SPAN>&nbsp;</P>
<P><SPAN style="COLOR: #000080"><SPAN style="FONT-FAMILY: 宋体; COLOR: #000080; FONT-SIZE: 10.5pt; mso-bidi-font-family: 宋体; mso-ansi-language: EN-US; mso-fareast-language: ZH-CN; mso-bidi-language: AR-SA" lang=EN-US>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</SPAN><SPAN style="FONT-FAMILY: 宋体; COLOR: #000080; FONT-SIZE: 10.5pt; mso-bidi-font-family: 宋体; mso-ansi-language: EN-US; mso-fareast-language: ZH-CN; mso-bidi-language: AR-SA"><SPAN style="COLOR: #000080">美好的时光总是太快，意犹未尽之时，我们该返程了。但蔚蓝的大海</SPAN>、柔软的沙滩、还有潮湿的海风，以及我们的开心快乐都将留在每个人的美好记忆里。</SPAN></SPAN></P>
<P><SPAN style="COLOR: #000080"><SPAN style="FONT-FAMILY: 宋体; COLOR: #000080; FONT-SIZE: 10.5pt; mso-bidi-font-family: 宋体; mso-ansi-language: EN-US; mso-fareast-language: ZH-CN; mso-bidi-language: AR-SA"></SPAN></SPAN>&nbsp;</P>
<P><SPAN style="COLOR: #000080"><SPAN style="FONT-FAMILY: 宋体; COLOR: #000080; FONT-SIZE: 10.5pt; mso-bidi-font-family: 宋体; mso-ansi-language: EN-US; mso-fareast-language: ZH-CN; mso-bidi-language: AR-SA"><IMG style="WIDTH: 441px; HEIGHT: 362px" border=0 alt="" src="http://www.clinet.com.cn/blog/UploadFiles/2010-7/23113427966.jpg" width=579 height=475></SPAN></SPAN></P>]]></description>
<author>华裕</author>
<pubDate>2010-7-19 14:23:00</pubDate>
</item>
<item>
<title><![CDATA[血清HE4 检测卵巢癌的总灵敏度]]></title>
<link>http://www.clinet.com.cn/blogu/109/archives/2010/4744.html</link>
<description><![CDATA[<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-SIZE: 12pt"><SPAN style="FONT-FAMILY: 宋体; mso-bidi-font-size: 10.5pt; mso-ascii-font-family: Arial; mso-bidi-font-family: Arial; mso-bidi-font-weight: bold">（</SPAN><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt; mso-bidi-font-weight: bold" lang=EN-US>% N=276) </SPAN><SPAN style="FONT-FAMILY: 宋体; mso-bidi-font-size: 10.5pt; mso-ascii-font-family: Arial; mso-bidi-font-family: Arial; mso-bidi-font-weight: bold">（对照为良性疾病）</SPAN><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt; mso-bidi-font-weight: bold" lang=EN-US><?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></SPAN></P>
<TABLE style="WIDTH: 384.75pt; mso-cellspacing: 0cm; mso-padding-alt: 0cm 0cm 0cm 0cm" class=MsoNormalTable border=0 cellSpacing=0 cellPadding=0 width=513>
<TBODY>
<TR style="HEIGHT: 27pt; mso-yfti-irow: 0; mso-yfti-firstrow: yes">
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1.5pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 129pt; PADDING-RIGHT: 0cm; HEIGHT: 27pt; BORDER-TOP: black 1.5pt solid; BORDER-RIGHT: black 1.5pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black 1.5pt; mso-border-bottom-alt: solid black .75pt" vAlign=bottom width=172>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: 宋体; mso-bidi-font-size: 10.5pt; mso-ascii-font-family: Arial; mso-bidi-font-family: Arial">标志物组合</SPAN><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US><o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1.5pt solid; BORDER-LEFT: black 1.5pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 84pt; PADDING-RIGHT: 0cm; HEIGHT: 27pt; BORDER-TOP: black 1.5pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black 1.5pt; mso-border-right-alt: solid black .75pt" width=112>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>ROC-AUC<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1.5pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 63pt; PADDING-RIGHT: 0cm; HEIGHT: 27pt; BORDER-TOP: black 1.5pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-right-alt: .75pt; mso-border-top-alt: 1.5pt; mso-border-left-alt: .75pt; mso-border-bottom-alt: 1.5pt; mso-border-color-alt: black; mso-border-style-alt: solid" vAlign=bottom width=84>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>90% <o:p></o:p></SPAN></P>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>Specificity<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1.5pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 60pt; PADDING-RIGHT: 0cm; HEIGHT: 27pt; BORDER-TOP: black 1.5pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-right-alt: .75pt; mso-border-top-alt: 1.5pt; mso-border-left-alt: .75pt; mso-border-bottom-alt: 1.5pt; mso-border-color-alt: black; mso-border-style-alt: solid" vAlign=bottom width=80>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>95% <o:p></o:p></SPAN></P>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>Specificity<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1.5pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 51.75pt; PADDING-RIGHT: 0cm; HEIGHT: 27pt; BORDER-TOP: black 1.5pt solid; BORDER-RIGHT: black 1.5pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black 1.5pt; mso-border-left-alt: solid black .75pt" vAlign=bottom width=69>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>98% Specificity<o:p></o:p></SPAN></P></TD></TR>
<TR style="HEIGHT: 16.5pt; mso-yfti-irow: 1">
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1.5pt solid; PADDING-BOTTOM: 0cm; PADDING-LEFT: 0cm; WIDTH: 129pt; PADDING-RIGHT: 0cm; BACKGROUND: yellow; HEIGHT: 16.5pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1.5pt solid; PADDING-TOP: 0cm; mso-border-right-alt: 1.5pt; mso-border-top-alt: .75pt; mso-border-left-alt: 1.5pt; mso-border-bottom-alt: .75pt; mso-border-color-alt: black; mso-border-style-alt: solid" vAlign=bottom width=172>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>CA125<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1.5pt solid; PADDING-BOTTOM: 0cm; PADDING-LEFT: 0cm; WIDTH: 84pt; PADDING-RIGHT: 0cm; BACKGROUND: yellow; HEIGHT: 16.5pt; BORDER-TOP: black 1.5pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-right-alt: .75pt; mso-border-top-alt: 1.5pt; mso-border-left-alt: 1.5pt; mso-border-bottom-alt: .75pt; mso-border-color-alt: black; mso-border-style-alt: solid" vAlign=bottom width=112>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>83 <o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; PADDING-LEFT: 0cm; WIDTH: 63pt; PADDING-RIGHT: 0cm; BACKGROUND: yellow; HEIGHT: 16.5pt; BORDER-TOP: black 1.5pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .75pt; mso-border-top-alt: solid black 1.5pt" vAlign=bottom width=84>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>59<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; PADDING-LEFT: 0cm; WIDTH: 60pt; PADDING-RIGHT: 0cm; BACKGROUND: yellow; HEIGHT: 16.5pt; BORDER-TOP: black 1.5pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .75pt; mso-border-top-alt: solid black 1.5pt" vAlign=bottom width=80>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>42<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; PADDING-LEFT: 0cm; WIDTH: 51.75pt; PADDING-RIGHT: 0cm; BACKGROUND: yellow; HEIGHT: 16.5pt; BORDER-TOP: black 1.5pt solid; BORDER-RIGHT: black 1.5pt solid; PADDING-TOP: 0cm; mso-border-right-alt: 1.5pt; mso-border-top-alt: 1.5pt; mso-border-left-alt: .75pt; mso-border-bottom-alt: .75pt; mso-border-color-alt: black; mso-border-style-alt: solid" vAlign=bottom width=69>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>23<o:p></o:p></SPAN></P></TD></TR>
<TR style="HEIGHT: 15.75pt; mso-yfti-irow: 2">
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1.5pt solid; PADDING-BOTTOM: 0cm; PADDING-LEFT: 0cm; WIDTH: 129pt; PADDING-RIGHT: 0cm; BACKGROUND: #ff7c80; HEIGHT: 15.75pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1.5pt solid; PADDING-TOP: 0cm; mso-border-right-alt: 1.5pt; mso-border-top-alt: .75pt; mso-border-left-alt: 1.5pt; mso-border-bottom-alt: .75pt; mso-border-color-alt: black; mso-border-style-alt: solid" vAlign=bottom width=172>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>HE4<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1.5pt solid; PADDING-BOTTOM: 0cm; PADDING-LEFT: 0cm; WIDTH: 84pt; PADDING-RIGHT: 0cm; BACKGROUND: #ff7c80; HEIGHT: 15.75pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .75pt; mso-border-left-alt: solid black 1.5pt" vAlign=bottom width=112>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>91 <o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; PADDING-LEFT: 0cm; WIDTH: 63pt; PADDING-RIGHT: 0cm; BACKGROUND: #ff7c80; HEIGHT: 15.75pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .75pt" vAlign=bottom width=84>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>77<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; PADDING-LEFT: 0cm; WIDTH: 60pt; PADDING-RIGHT: 0cm; BACKGROUND: #ff7c80; HEIGHT: 15.75pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .75pt" vAlign=bottom width=80>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>71<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; PADDING-LEFT: 0cm; WIDTH: 51.75pt; PADDING-RIGHT: 0cm; BACKGROUND: #ff7c80; HEIGHT: 15.75pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1.5pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .75pt; mso-border-right-alt: solid black 1.5pt" vAlign=bottom width=69>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>62<o:p></o:p></SPAN></P></TD></TR>
<TR style="HEIGHT: 16.5pt; mso-yfti-irow: 3">
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1.5pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 129pt; PADDING-RIGHT: 0cm; HEIGHT: 16.5pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1.5pt solid; PADDING-TOP: 0cm; mso-border-right-alt: 1.5pt; mso-border-top-alt: .75pt; mso-border-left-alt: 1.5pt; mso-border-bottom-alt: .75pt; mso-border-color-alt: black; mso-border-style-alt: solid" vAlign=bottom width=172>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>SMRP<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1.5pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 84pt; PADDING-RIGHT: 0cm; HEIGHT: 16.5pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .75pt; mso-border-left-alt: solid black 1.5pt" vAlign=bottom width=112>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>83 <o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 63pt; PADDING-RIGHT: 0cm; HEIGHT: 16.5pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .75pt" vAlign=bottom width=84>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>61<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 60pt; PADDING-RIGHT: 0cm; HEIGHT: 16.5pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .75pt" vAlign=bottom width=80>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>54<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 51.75pt; PADDING-RIGHT: 0cm; HEIGHT: 16.5pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1.5pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .75pt; mso-border-right-alt: solid black 1.5pt" vAlign=bottom width=69>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>44<o:p></o:p></SPAN></P></TD></TR>
<TR style="HEIGHT: 15.75pt; mso-yfti-irow: 4">
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1.5pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 129pt; PADDING-RIGHT: 0cm; HEIGHT: 15.75pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1.5pt solid; PADDING-TOP: 0cm; mso-border-right-alt: 1.5pt; mso-border-top-alt: .75pt; mso-border-left-alt: 1.5pt; mso-border-bottom-alt: .75pt; mso-border-color-alt: black; mso-border-style-alt: solid" vAlign=bottom width=172>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>CA72-4<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1.5pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 84pt; PADDING-RIGHT: 0cm; HEIGHT: 15.75pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .75pt; mso-border-left-alt: solid black 1.5pt" vAlign=bottom width=112>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>77 <o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 63pt; PADDING-RIGHT: 0cm; HEIGHT: 15.75pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .75pt" vAlign=bottom width=84>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>42<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 60pt; PADDING-RIGHT: 0cm; HEIGHT: 15.75pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .75pt" vAlign=bottom width=80>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>31<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 51.75pt; PADDING-RIGHT: 0cm; HEIGHT: 15.75pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1.5pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .75pt; mso-border-right-alt: solid black 1.5pt" vAlign=bottom width=69>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>23<o:p></o:p></SPAN></P></TD></TR>
<TR style="HEIGHT: 15.75pt; mso-yfti-irow: 5">
<TD style="BORDER-BOTTOM: black 1.5pt solid; BORDER-LEFT: black 1.5pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 129pt; PADDING-RIGHT: 0cm; HEIGHT: 15.75pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1.5pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black 1.5pt; mso-border-top-alt: solid black .75pt" vAlign=bottom width=172>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>Inhibin<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1.5pt solid; BORDER-LEFT: black 1.5pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 84pt; PADDING-RIGHT: 0cm; HEIGHT: 15.75pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-right-alt: .75pt; mso-border-top-alt: .75pt; mso-border-left-alt: 1.5pt; mso-border-bottom-alt: 1.5pt; mso-border-color-alt: black; mso-border-style-alt: solid" vAlign=bottom width=112>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>35<SPAN style="mso-spacerun: yes">&nbsp; </SPAN><o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1.5pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 63pt; PADDING-RIGHT: 0cm; HEIGHT: 15.75pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .75pt; mso-border-bottom-alt: solid black 1.5pt" vAlign=bottom width=84>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>7<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1.5pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 60pt; PADDING-RIGHT: 0cm; HEIGHT: 15.75pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .75pt; mso-border-bottom-alt: solid black 1.5pt" vAlign=bottom width=80>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>0<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1.5pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 51.75pt; PADDING-RIGHT: 0cm; HEIGHT: 15.75pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1.5pt solid; PADDING-TOP: 0cm; mso-border-right-alt: 1.5pt; mso-border-top-alt: .75pt; mso-border-left-alt: .75pt; mso-border-bottom-alt: 1.5pt; mso-border-color-alt: black; mso-border-style-alt: solid" vAlign=bottom width=69>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>0<o:p></o:p></SPAN></P></TD></TR>
<TR style="HEIGHT: 15.75pt; mso-yfti-irow: 6">
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1.5pt solid; PADDING-BOTTOM: 0cm; PADDING-LEFT: 0cm; WIDTH: 129pt; PADDING-RIGHT: 0cm; BACKGROUND: #ffcc66; HEIGHT: 15.75pt; BORDER-TOP: black 1.5pt solid; BORDER-RIGHT: black 1.5pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black 1.5pt; mso-border-bottom-alt: solid black .75pt" vAlign=bottom width=172>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>CA125 + HE4<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1.5pt solid; PADDING-BOTTOM: 0cm; PADDING-LEFT: 0cm; WIDTH: 84pt; PADDING-RIGHT: 0cm; BACKGROUND: #ffcc66; HEIGHT: 15.75pt; BORDER-TOP: black 1.5pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-right-alt: .75pt; mso-border-top-alt: 1.5pt; mso-border-left-alt: 1.5pt; mso-border-bottom-alt: .75pt; mso-border-color-alt: black; mso-border-style-alt: solid" vAlign=bottom width=112>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>91 <o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; PADDING-LEFT: 0cm; WIDTH: 63pt; PADDING-RIGHT: 0cm; BACKGROUND: #ffcc66; HEIGHT: 15.75pt; BORDER-TOP: black 1.5pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .75pt; mso-border-top-alt: solid black 1.5pt" vAlign=bottom width=84>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>81<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; PADDING-LEFT: 0cm; WIDTH: 60pt; PADDING-RIGHT: 0cm; BACKGROUND: #ffcc66; HEIGHT: 15.75pt; BORDER-TOP: black 1.5pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .75pt; mso-border-top-alt: solid black 1.5pt" vAlign=bottom width=80>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>77 <o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; PADDING-LEFT: 0cm; WIDTH: 51.75pt; PADDING-RIGHT: 0cm; BACKGROUND: #ffcc66; HEIGHT: 15.75pt; BORDER-TOP: black 1.5pt solid; BORDER-RIGHT: black 1.5pt solid; PADDING-TOP: 0cm; mso-border-right-alt: 1.5pt; mso-border-top-alt: 1.5pt; mso-border-left-alt: .75pt; mso-border-bottom-alt: .75pt; mso-border-color-alt: black; mso-border-style-alt: solid" vAlign=bottom width=69>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>68<o:p></o:p></SPAN></P></TD></TR>
<TR style="HEIGHT: 15.75pt; mso-yfti-irow: 7">
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1.5pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 129pt; PADDING-RIGHT: 0cm; HEIGHT: 15.75pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1.5pt solid; PADDING-TOP: 0cm; mso-border-right-alt: 1.5pt; mso-border-top-alt: .75pt; mso-border-left-alt: 1.5pt; mso-border-bottom-alt: .75pt; mso-border-color-alt: black; mso-border-style-alt: solid" vAlign=bottom width=172>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>CA125 + CA72-4<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1.5pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 84pt; PADDING-RIGHT: 0cm; HEIGHT: 15.75pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .75pt; mso-border-left-alt: solid black 1.5pt" vAlign=bottom width=112>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>85<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 63pt; PADDING-RIGHT: 0cm; HEIGHT: 15.75pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .75pt" vAlign=bottom width=84>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>61<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 60pt; PADDING-RIGHT: 0cm; HEIGHT: 15.75pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .75pt" vAlign=bottom width=80>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>45<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 51.75pt; PADDING-RIGHT: 0cm; HEIGHT: 15.75pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1.5pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .75pt; mso-border-right-alt: solid black 1.5pt" vAlign=bottom width=69>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>31<o:p></o:p></SPAN></P></TD></TR>
<TR style="HEIGHT: 15.75pt; mso-yfti-irow: 8">
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1.5pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 129pt; PADDING-RIGHT: 0cm; HEIGHT: 15.75pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1.5pt solid; PADDING-TOP: 0cm; mso-border-right-alt: 1.5pt; mso-border-top-alt: .75pt; mso-border-left-alt: 1.5pt; mso-border-bottom-alt: .75pt; mso-border-color-alt: black; mso-border-style-alt: solid" vAlign=bottom width=172>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>CA125 + HE4 + SMRP<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1.5pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 84pt; PADDING-RIGHT: 0cm; HEIGHT: 15.75pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .75pt; mso-border-left-alt: solid black 1.5pt" vAlign=bottom width=112>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>91 <o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 63pt; PADDING-RIGHT: 0cm; HEIGHT: 15.75pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .75pt" vAlign=bottom width=84>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>80<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 60pt; PADDING-RIGHT: 0cm; HEIGHT: 15.75pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .75pt" vAlign=bottom width=80>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>73<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 51.75pt; PADDING-RIGHT: 0cm; HEIGHT: 15.75pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1.5pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .75pt; mso-border-right-alt: solid black 1.5pt" vAlign=bottom width=69>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>70<o:p></o:p></SPAN></P></TD></TR>
<TR style="HEIGHT: 15.75pt; mso-yfti-irow: 9">
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1.5pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 129pt; PADDING-RIGHT: 0cm; HEIGHT: 15.75pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1.5pt solid; PADDING-TOP: 0cm; mso-border-right-alt: 1.5pt; mso-border-top-alt: .75pt; mso-border-left-alt: 1.5pt; mso-border-bottom-alt: .75pt; mso-border-color-alt: black; mso-border-style-alt: solid" vAlign=bottom width=172>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>CA125 + HE4 + CA72-4<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1.5pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 84pt; PADDING-RIGHT: 0cm; HEIGHT: 15.75pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .75pt; mso-border-left-alt: solid black 1.5pt" vAlign=bottom width=112>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>91<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 63pt; PADDING-RIGHT: 0cm; HEIGHT: 15.75pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .75pt" vAlign=bottom width=84>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>81<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 60pt; PADDING-RIGHT: 0cm; HEIGHT: 15.75pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .75pt" vAlign=bottom width=80>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>77<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 51.75pt; PADDING-RIGHT: 0cm; HEIGHT: 15.75pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1.5pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .75pt; mso-border-right-alt: solid black 1.5pt" vAlign=bottom width=69>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>68<o:p></o:p></SPAN></P></TD></TR>
<TR style="HEIGHT: 15.75pt; mso-yfti-irow: 10">
<TD style="BORDER-BOTTOM: black 1.5pt solid; BORDER-LEFT: black 1.5pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 129pt; PADDING-RIGHT: 0cm; HEIGHT: 15.75pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1.5pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black 1.5pt; mso-border-top-alt: solid black .75pt" vAlign=bottom width=172>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>CA125 + HE4 + Inhibin<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1.5pt solid; BORDER-LEFT: black 1.5pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 84pt; PADDING-RIGHT: 0cm; HEIGHT: 15.75pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-right-alt: .75pt; mso-border-top-alt: .75pt; mso-border-left-alt: 1.5pt; mso-border-bottom-alt: 1.5pt; mso-border-color-alt: black; mso-border-style-alt: solid" vAlign=bottom width=112>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>91 <o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1.5pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 63pt; PADDING-RIGHT: 0cm; HEIGHT: 15.75pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .75pt; mso-border-bottom-alt: solid black 1.5pt" vAlign=bottom width=84>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>80<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1.5pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 60pt; PADDING-RIGHT: 0cm; HEIGHT: 15.75pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .75pt; mso-border-bottom-alt: solid black 1.5pt" vAlign=bottom width=80>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>76<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1.5pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 51.75pt; PADDING-RIGHT: 0cm; HEIGHT: 15.75pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1.5pt solid; PADDING-TOP: 0cm; mso-border-right-alt: 1.5pt; mso-border-top-alt: .75pt; mso-border-left-alt: .75pt; mso-border-bottom-alt: 1.5pt; mso-border-color-alt: black; mso-border-style-alt: solid" vAlign=bottom width=69>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>67<o:p></o:p></SPAN></P></TD></TR>
<TR style="HEIGHT: 27pt; mso-yfti-irow: 11; mso-yfti-lastrow: yes">
<TD style="BORDER-BOTTOM: black 1.5pt solid; BORDER-LEFT: black 1.5pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 129pt; PADDING-RIGHT: 0cm; HEIGHT: 27pt; BORDER-TOP: black 1.5pt solid; BORDER-RIGHT: black 1.5pt solid; PADDING-TOP: 0cm" vAlign=bottom width=172>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>CA125 + HE4 + <o:p></o:p></SPAN></P>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>SMRP + CA72-4<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1.5pt solid; BORDER-LEFT: black 1.5pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 84pt; PADDING-RIGHT: 0cm; HEIGHT: 27pt; BORDER-TOP: black 1.5pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black 1.5pt; mso-border-right-alt: solid black .75pt" vAlign=bottom width=112>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>91% <o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1.5pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 63pt; PADDING-RIGHT: 0cm; HEIGHT: 27pt; BORDER-TOP: black 1.5pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-right-alt: .75pt; mso-border-top-alt: 1.5pt; mso-border-left-alt: .75pt; mso-border-bottom-alt: 1.5pt; mso-border-color-alt: black; mso-border-style-alt: solid" vAlign=bottom width=84>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>81%<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1.5pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 60pt; PADDING-RIGHT: 0cm; HEIGHT: 27pt; BORDER-TOP: black 1.5pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-right-alt: .75pt; mso-border-top-alt: 1.5pt; mso-border-left-alt: .75pt; mso-border-bottom-alt: 1.5pt; mso-border-color-alt: black; mso-border-style-alt: solid" vAlign=bottom width=80>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>73%<o:p></o:p></SPAN></P></TD>
<TD style="BORDER-BOTTOM: black 1.5pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0cm; WIDTH: 51.75pt; PADDING-RIGHT: 0cm; HEIGHT: 27pt; BORDER-TOP: black 1.5pt solid; BORDER-RIGHT: black 1.5pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black 1.5pt; mso-border-left-alt: solid black .75pt" vAlign=bottom width=69>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US>70%<o:p></o:p></SPAN></P></TD></TR></TBODY></TABLE>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; mso-bidi-font-size: 10.5pt" lang=EN-US><o:p><SPAN style="FONT-SIZE: 12pt">&nbsp;</SPAN></o:p></SPAN></P>]]></description>
<author>华裕</author>
<pubDate>2010-7-16 9:23:00</pubDate>
</item>
<item>
<title><![CDATA[天津华裕参加2010年山西临检会]]></title>
<link>http://www.clinet.com.cn/blogu/109/archives/2010/4707.html</link>
<description><![CDATA[<SPAN style="COLOR: #c709f7">&nbsp;&nbsp;&nbsp;&nbsp;<SPAN style="COLOR: #000000">&nbsp;&nbsp;&nbsp;<SPAN style="COLOR: #000000"><SPAN style="COLOR: #000000; FONT-SIZE: 12pt">2010年3月28日至31日，2010年山西省临床检验室间质量评价总结暨学术研讨会在太原召开。会议将特别邀请国内著名专家、学者作有关“临床检验新技术、新进展”专题学术讲座。</SPAN></SPAN></SPAN></SPAN><SPAN style="COLOR: #000000"></SPAN>
<DIV><SPAN style="COLOR: #000000; FONT-SIZE: 12pt"></SPAN>&nbsp;</DIV>
<DIV><SPAN style="COLOR: #000000; FONT-SIZE: 12pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 我公司展出的<B>XD蛋白印迹仪</B>引起了众多与会者的关注，它有着批量处理，中文界面，用于多种检测等特点，可以解放人力。有合作意向者众多。</SPAN></DIV>
<DIV><SPAN style="COLOR: #dda0dd; FONT-SIZE: 12pt"></SPAN>&nbsp;</DIV>
<DIV><SPAN style="COLOR: #c709f7; FONT-SIZE: 12pt"><IMG style="WIDTH: 395px; HEIGHT: 277px" border=0 alt="" src="http://www.clinet.com.cn/blog/UploadFiles/2010-7/91438771590.jpg" width=511 height=356></SPAN></DIV>]]></description>
<author>华裕</author>
<pubDate>2010-7-9 14:37:00</pubDate>
</item>
<item>
<title><![CDATA[天津华裕参加2009年天津临床检验年终会]]></title>
<link>http://www.clinet.com.cn/blogu/109/archives/2010/4706.html</link>
<description><![CDATA[<P><SPAN style="FONT-FAMILY: 幼圆; COLOR: #c211ee; FONT-SIZE: 12pt">&nbsp;&nbsp;&nbsp;<SPAN style="COLOR: #000000">&nbsp;2009年天津临床检验年终会议于2010年03月12-14日在天津市宝坻区天宝会议中心举行。此次会议参会人员为来自天津市各检验机构代表约300余人。</SPAN></SPAN></P>
<DIV><SPAN style="COLOR: #000000"></SPAN>&nbsp;</DIV>
<DIV><SPAN style="FONT-FAMILY: 幼圆; COLOR: #000000; FONT-SIZE: 12pt">&nbsp;&nbsp;&nbsp;&nbsp;我公司在本次展会展出了最新代理的<B>XD蛋白印迹仪</B>，吸引了广大专业人士和经销商的极大关注。XD蛋白印迹仪有着批量处理，中文界面，用于多种检测等特点，可以解放人力。公司展台前参观人员络绎不绝，提高了我公司检验产品在天津市场的知名度。</SPAN></DIV>
<DIV><SPAN style="FONT-FAMILY: 幼圆; COLOR: #c211ee; FONT-SIZE: 12pt"></SPAN>&nbsp;</DIV>
<DIV><SPAN style="FONT-FAMILY: 幼圆; COLOR: #c211ee; FONT-SIZE: 12pt">&nbsp;<IMG border=0 alt="" src="http://www.clinet.com.cn/blog/UploadFiles/2010-7/161447339210.jpg"></SPAN></DIV>
<DIV><SPAN style="FONT-FAMILY: 幼圆; COLOR: #c211ee; FONT-SIZE: 12pt"></SPAN>&nbsp;</DIV>
<DIV><SPAN style="FONT-FAMILY: 幼圆; COLOR: #c211ee; FONT-SIZE: 12pt"></SPAN>&nbsp;</DIV>]]></description>
<author>华裕</author>
<pubDate>2010-7-8 15:51:00</pubDate>
</item>
<item>
<title><![CDATA[天津华裕公司代理XD自动蛋白印迹仪。]]></title>
<link>http://www.clinet.com.cn/blogu/109/archives/2010/4705.html</link>
<description><![CDATA[<SPAN style="FONT-SIZE: 12pt">&nbsp;&nbsp;&nbsp;&nbsp;<SPAN style="COLOR: #dda0dd">&nbsp; <SPAN style="COLOR: #006400">从2010年1月1日起我公司代理<STRONG>XD</STRONG><STRONG>自动蛋白印迹仪</STRONG>。</SPAN></SPAN></SPAN> 
<DIV align=left><SPAN style="COLOR: #006400"></SPAN>&nbsp;</DIV>
<DIV align=left><SPAN style="COLOR: #006400; FONT-SIZE: 12pt"></SPAN></DIV>
<DIV align=left><SPAN style="COLOR: #006400; FONT-SIZE: 12pt">&nbsp;&nbsp;&nbsp;&nbsp; 自动蛋白印迹仪是一台智能化自动操作仪器,每次实验只需手工加膜条和样品，其他操作全部实现自动化。蛋白（免疫）印迹或其他类似方法试剂盒均可在此机器上完成自动化操作，如HIV，HCV，HTLV，HP等各种疾病原体确认和检测；风湿病相关的自身抗体检测、特应性过敏抗原印迹法检测和肝抗原谱印迹法检测等。</SPAN></DIV>
<DIV align=left><SPAN style="COLOR: #006400; FONT-SIZE: 12pt"></SPAN>&nbsp;</DIV>
<DIV align=left><SPAN style="COLOR: #006400; FONT-SIZE: 12pt">&nbsp;&nbsp;&nbsp;&nbsp; 仪器可同时检测36条带，全中文人机对话。 </SPAN></DIV>
<DIV align=left><SPAN style="COLOR: #006400; FONT-SIZE: 12pt"></SPAN>&nbsp;</DIV>
<DIV align=left><STRONG><SPAN style="COLOR: #006400; FONT-SIZE: 12pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;解放人力，同时减少人为误差，结果更准确。</SPAN></STRONG></DIV>
<DIV align=left><STRONG><SPAN style="COLOR: #006400; FONT-SIZE: 12pt"><IMG style="WIDTH: 417px; HEIGHT: 317px" border=0 alt="" src="http://www.clinet.com.cn/blog/UploadFiles/2010-7/71033998444.jpg" width=579 height=386></SPAN></STRONG></DIV>]]></description>
<author>华裕</author>
<pubDate>2010-7-7 8:53:00</pubDate>
</item>
<item>
<title><![CDATA[ANA（12）项的检测意义-- 抗Jo-1抗体检测意义]]></title>
<link>http://www.clinet.com.cn/blogu/109/archives/2010/4695.html</link>
<description><![CDATA[<P style="WORD-BREAK: break-all"><SPAN lang=EN-US><?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /><o:p><SPAN style="FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt"><SPAN style="FONT-SIZE: 10pt"><SPAN lang=EN-US><o:p><SPAN style="FONT-SIZE: 12pt"><SPAN style="FONT-FAMILY: 宋体; FONT-SIZE: 12pt; mso-bidi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: ZH-CN; mso-bidi-language: AR-SA; mso-bidi-font-size: 9.0pt"><SPAN style="COLOR: #c71585"><SPAN style="FONT-FAMILY: 楷体_GB2312; COLOR: #c71585; FONT-SIZE: 18pt; mso-bidi-font-size: 9.0pt; mso-font-kerning: 0pt" lang=EN-US><SPAN style="COLOR: #c71585; FONT-SIZE: 18pt"><SPAN style="FONT-FAMILY: 楷体_GB2312; COLOR: #c71585; FONT-SIZE: 18pt; mso-hansi-font-family: 宋体; mso-bidi-font-size: 9.0pt; mso-font-kerning: 0pt" lang=EN-US><SPAN style="COLOR: #c71585; FONT-SIZE: 18pt"><SPAN style="FONT-FAMILY: 楷体_GB2312; COLOR: #c71585; FONT-SIZE: 18pt; mso-bidi-font-size: 9.0pt; mso-font-kerning: 0pt" lang=EN-US>1</SPAN><SPAN style="FONT-FAMILY: 楷体_GB2312; COLOR: #c71585; FONT-SIZE: 18pt; mso-hansi-font-family: 宋体; mso-bidi-font-size: 9.0pt; mso-font-kerning: 0pt">、抗<SPAN style="COLOR: #c71585; FONT-SIZE: 18pt" lang=EN-US>Jo-1</SPAN>抗体为多发性肌炎／皮肌炎（<SPAN style="COLOR: #c71585; FONT-SIZE: 18pt" lang=EN-US>PM</SPAN>／<SPAN style="COLOR: #c71585; FONT-SIZE: 18pt" lang=EN-US>DM</SPAN>）的血清标记性抗体，在<SPAN style="COLOR: #c71585; FONT-SIZE: 18pt" lang=EN-US>PM</SPAN>／<SPAN style="COLOR: #c71585; FONT-SIZE: 18pt" lang=EN-US>DM</SPAN></SPAN><SPAN style="FONT-FAMILY: 楷体_GB2312; COLOR: #c71585; FONT-SIZE: 18pt; mso-bidi-font-size: 9.0pt; mso-font-kerning: 0pt" lang=EN-US> </SPAN><SPAN style="FONT-FAMILY: 楷体_GB2312; COLOR: #c71585; FONT-SIZE: 18pt; mso-hansi-font-family: 宋体; mso-bidi-font-size: 9.0pt; mso-font-kerning: 0pt">中的阳性率为<SPAN style="COLOR: #c71585; FONT-SIZE: 18pt" lang=EN-US>20%-30%</SPAN>，且多数患者伴有间质性肺部疾病（<SPAN style="COLOR: #c71585; FONT-SIZE: 18pt" lang=EN-US>ILD</SPAN>）和多关节炎或关节痛等。</SPAN><SPAN style="FONT-FAMILY: 楷体_GB2312; COLOR: #c71585; FONT-SIZE: 18pt; mso-bidi-font-size: 9.0pt; mso-font-kerning: 0pt" lang=EN-US><o:p></o:p></SPAN></SPAN></P>
<DIV align=justify>
<DIV style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 1pt; PADDING-LEFT: 0cm; PADDING-RIGHT: 0cm; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0cm; mso-element: para-border-div; mso-border-bottom-alt: solid windowtext .75pt">
<DIV style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 1pt; PADDING-LEFT: 0cm; PADDING-RIGHT: 0cm; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0cm; mso-element: para-border-div; mso-border-bottom-alt: solid windowtext .75pt">
<DIV style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 1pt; PADDING-LEFT: 0cm; PADDING-RIGHT: 0cm; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0cm; mso-element: para-border-div; mso-border-bottom-alt: solid windowtext .75pt">
<P style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0cm; MARGIN: 0cm 0cm 0pt; PADDING-LEFT: 0cm; LAYOUT-GRID-MODE: char; PADDING-RIGHT: 0cm; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0cm; tab-stops: center 207.65pt right 415.3pt; mso-border-bottom-alt: solid windowtext .75pt; mso-padding-alt: 0cm 0cm 1.0pt 0cm; mso-layout-grid-align: none" class=MsoNormal><SPAN style="COLOR: #c71585; FONT-SIZE: 18pt"><SPAN style="FONT-FAMILY: 楷体_GB2312; COLOR: #c71585; FONT-SIZE: 18pt; mso-bidi-font-size: 9.0pt; mso-font-kerning: 0pt" lang=EN-US>2</SPAN><SPAN style="FONT-FAMILY: 楷体_GB2312; COLOR: #c71585; FONT-SIZE: 18pt; mso-hansi-font-family: 宋体; mso-bidi-font-size: 9.0pt; mso-font-kerning: 0pt">、多发性肌炎患者中以抗<SPAN style="COLOR: #c71585; FONT-SIZE: 18pt" lang=EN-US>Jo-1</SPAN>抗体更多见，而皮肌炎患者则以其他一些抗氨酰<SPAN style="COLOR: #c71585; FONT-SIZE: 18pt" lang=EN-US>tRNA</SPAN>合成酶抗体更为多见。抗<SPAN style="COLOR: #c71585; FONT-SIZE: 18pt" lang=EN-US>Jo-1</SPAN>抗体在<SPAN style="COLOR: #c71585; FONT-SIZE: 18pt" lang=EN-US>PM</SPAN>中阳性率可达<SPAN style="COLOR: #c71585; FONT-SIZE: 18pt" lang=EN-US>40%</SPAN>，在<SPAN style="COLOR: #c71585; FONT-SIZE: 18pt" lang=EN-US>DM</SPAN>中约<SPAN style="COLOR: #c71585; FONT-SIZE: 18pt" lang=EN-US>5%</SPAN>，非肌炎患者未发现阳性。</SPAN><SPAN style="FONT-FAMILY: 楷体_GB2312; COLOR: #c71585; FONT-SIZE: 18pt; mso-bidi-font-size: 9.0pt; mso-font-kerning: 0pt" lang=EN-US><o:p></o:p></SPAN></SPAN></P>
<P style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0cm; MARGIN: 0cm 0cm 0pt; PADDING-LEFT: 0cm; LAYOUT-GRID-MODE: char; PADDING-RIGHT: 0cm; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0cm; tab-stops: center 207.65pt right 415.3pt; mso-border-bottom-alt: solid windowtext .75pt; mso-padding-alt: 0cm 0cm 1.0pt 0cm; mso-layout-grid-align: none" class=MsoNormal><SPAN style="COLOR: #c71585; FONT-SIZE: 18pt"><SPAN style="FONT-FAMILY: 楷体_GB2312; COLOR: #c71585; FONT-SIZE: 18pt; mso-bidi-font-size: 9.0pt; mso-font-kerning: 0pt" lang=EN-US>3</SPAN><SPAN style="FONT-FAMILY: 楷体_GB2312; COLOR: #c71585; FONT-SIZE: 18pt; mso-hansi-font-family: 宋体; mso-bidi-font-size: 9.0pt; mso-font-kerning: 0pt">、在合并肺间质病变的<SPAN style="COLOR: #c71585; FONT-SIZE: 18pt" lang=EN-US>PM</SPAN>／<SPAN style="COLOR: #c71585; FONT-SIZE: 18pt" lang=EN-US>DM</SPAN></SPAN><SPAN style="FONT-FAMILY: 楷体_GB2312; COLOR: #c71585; FONT-SIZE: 18pt; mso-bidi-font-size: 9.0pt; mso-font-kerning: 0pt" lang=EN-US> </SPAN><SPAN style="FONT-FAMILY: 楷体_GB2312; COLOR: #c71585; FONT-SIZE: 18pt; mso-hansi-font-family: 宋体; mso-bidi-font-size: 9.0pt; mso-font-kerning: 0pt">患者中，抗<SPAN style="COLOR: #c71585; FONT-SIZE: 18pt" lang=EN-US>Jo-1</SPAN>抗体的阳性率高达<SPAN style="COLOR: #c71585; FONT-SIZE: 18pt" lang=EN-US>60%</SPAN>。</SPAN><SPAN style="FONT-FAMILY: 楷体_GB2312; COLOR: #c71585; FONT-SIZE: 18pt; mso-bidi-font-size: 9.0pt; mso-font-kerning: 0pt" lang=EN-US><o:p></o:p></SPAN></SPAN></P>
<P style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0cm; MARGIN: 0cm 0cm 0pt; PADDING-LEFT: 0cm; LAYOUT-GRID-MODE: char; PADDING-RIGHT: 0cm; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0cm; tab-stops: center 207.65pt right 415.3pt; mso-border-bottom-alt: solid windowtext .75pt; mso-padding-alt: 0cm 0cm 1.0pt 0cm; mso-layout-grid-align: none" class=MsoNormal><SPAN style="COLOR: #c71585; FONT-SIZE: 18pt"><SPAN style="FONT-FAMILY: 楷体_GB2312; COLOR: #c71585; FONT-SIZE: 18pt; mso-hansi-font-family: 宋体; mso-bidi-font-size: 9.0pt; mso-font-kerning: 0pt">抗<SPAN style="COLOR: #c71585; FONT-SIZE: 18pt" lang=EN-US>Jo-1</SPAN>抗体对肌炎的诊断具有较高特异性（＞<SPAN style="COLOR: #c71585; FONT-SIZE: 18pt" lang=EN-US>95%</SPAN>），抗体的效价与疾病的活动性相关，与患者的肌酸激酶水平及肌炎活动的临床指标有关。</SPAN><SPAN style="FONT-FAMILY: 楷体_GB2312; COLOR: #c71585; FONT-SIZE: 18pt; mso-bidi-font-size: 9.0pt; mso-font-kerning: 0pt" lang=EN-US><o:p></o:p></SPAN></SPAN></P>
<P style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0cm; MARGIN: 0cm 0cm 0pt; PADDING-LEFT: 0cm; LAYOUT-GRID-MODE: char; PADDING-RIGHT: 0cm; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0cm; tab-stops: center 207.65pt right 415.3pt; mso-border-bottom-alt: solid windowtext .75pt; mso-padding-alt: 0cm 0cm 1.0pt 0cm; mso-layout-grid-align: none" class=MsoNormal><SPAN style="COLOR: #c71585; FONT-SIZE: 18pt"><SPAN style="FONT-FAMILY: 楷体_GB2312; COLOR: #c71585; FONT-SIZE: 18pt; mso-bidi-font-size: 9.0pt; mso-font-kerning: 0pt" lang=EN-US>4</SPAN><SPAN style="FONT-FAMILY: 楷体_GB2312; COLOR: #c71585; FONT-SIZE: 18pt; mso-hansi-font-family: 宋体; mso-bidi-font-size: 9.0pt; mso-font-kerning: 0pt">、临床上将急性发热、对称性关节炎、</SPAN><SPAN style="FONT-FAMILY: 楷体_GB2312; COLOR: #c71585; FONT-SIZE: 18pt; mso-bidi-font-size: 9.0pt; mso-font-kerning: 0pt">“</SPAN><SPAN style="FONT-FAMILY: 楷体_GB2312; COLOR: #c71585; FONT-SIZE: 18pt; mso-hansi-font-family: 宋体; mso-bidi-font-size: 9.0pt; mso-font-kerning: 0pt">技工手</SPAN><SPAN style="FONT-FAMILY: 楷体_GB2312; COLOR: #c71585; FONT-SIZE: 18pt; mso-bidi-font-size: 9.0pt; mso-font-kerning: 0pt">”</SPAN><SPAN style="FONT-FAMILY: 楷体_GB2312; COLOR: #c71585; FONT-SIZE: 18pt; mso-hansi-font-family: 宋体; mso-bidi-font-size: 9.0pt; mso-font-kerning: 0pt">（机械手）、雷诺现象、肌炎合并有肺间质病变且抗<SPAN style="COLOR: #c71585; FONT-SIZE: 18pt" lang=EN-US>Jo-1</SPAN>抗体为阳性的表现，称为</SPAN><SPAN style="FONT-FAMILY: 楷体_GB2312; COLOR: #c71585; FONT-SIZE: 18pt; mso-bidi-font-size: 9.0pt; mso-font-kerning: 0pt">“</SPAN><SPAN style="FONT-FAMILY: 楷体_GB2312; COLOR: #c71585; FONT-SIZE: 18pt; mso-hansi-font-family: 宋体; mso-bidi-font-size: 9.0pt; mso-font-kerning: 0pt">抗<SPAN style="COLOR: #c71585; FONT-SIZE: 18pt" lang=EN-US>Jo-1</SPAN>抗体综合征</SPAN><SPAN style="FONT-FAMILY: 楷体_GB2312; COLOR: #c71585; FONT-SIZE: 18pt; mso-bidi-font-size: 9.0pt; mso-font-kerning: 0pt">”</SPAN><SPAN style="FONT-FAMILY: 楷体_GB2312; COLOR: #c71585; FONT-SIZE: 18pt; mso-hansi-font-family: 宋体; mso-bidi-font-size: 9.0pt; mso-font-kerning: 0pt">。</SPAN><SPAN style="FONT-FAMILY: 楷体_GB2312; COLOR: #c71585; FONT-SIZE: 18pt; mso-bidi-font-size: 9.0pt; mso-font-kerning: 0pt" lang=EN-US><o:p></o:p></SPAN></SPAN></P></DIV>
<P style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0cm; MARGIN: 0cm 0cm 0pt; PADDING-LEFT: 0cm; LAYOUT-GRID-MODE: char; PADDING-RIGHT: 0cm; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0cm; tab-stops: center 207.65pt right 415.3pt; mso-border-bottom-alt: solid windowtext .75pt; mso-padding-alt: 0cm 0cm 1.0pt 0cm; mso-layout-grid-align: none" class=MsoNormal><SPAN style="COLOR: #c71585; FONT-SIZE: 18pt"><SPAN style="FONT-FAMILY: 楷体_GB2312; COLOR: #c71585; FONT-SIZE: 18pt; mso-bidi-font-family: 'Times New Roman'; mso-hansi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: ZH-CN; mso-bidi-language: AR-SA; mso-bidi-font-size: 9.0pt; mso-font-kerning: 0pt" lang=EN-US>5</SPAN><SPAN style="FONT-FAMILY: 楷体_GB2312; COLOR: #c71585; FONT-SIZE: 18pt; mso-bidi-font-family: 'Times New Roman'; mso-hansi-font-family: 宋体; mso-ansi-language: EN-US; mso-fareast-language: ZH-CN; mso-bidi-language: AR-SA; mso-bidi-font-size: 9.0pt; mso-font-kerning: 0pt">、抗<SPAN style="COLOR: #c71585; FONT-SIZE: 18pt" lang=EN-US>Jo-1</SPAN>抗体阳性的肌炎患者与抗体阴性者相比，前者发病年龄相对较轻、病情进展快、疗效差、肌力和酶完全恢复的可能性小、停药易复发。</SPAN></SPAN></SPAN></SPAN></P></SPAN></SPAN></DIV></DIV>
<P style="MARGIN: 7.8pt 0cm" class=MsoNormal><SPAN style="FONT-FAMILY: 楷体_GB2312; FONT-SIZE: 12pt; mso-bidi-font-family: 'Times New Roman'; mso-hansi-font-family: 宋体; mso-ansi-language: EN-US; mso-fareast-language: ZH-CN; mso-bidi-language: AR-SA; mso-bidi-font-size: 9.0pt; mso-font-kerning: 0pt"></SPAN></SPAN>&nbsp;</SPAN></o:p></SPAN></SPAN></SPAN></o:p></SPAN></P></DIV>]]></description>
<author>华裕</author>
<pubDate>2010-6-28 11:43:00</pubDate>
</item>
<item>
<title><![CDATA[ANA（12）项的检测意义--抗着丝点B（Cenp-B）抗体]]></title>
<link>http://www.clinet.com.cn/blogu/109/archives/2010/4694.html</link>
<description><![CDATA[<P style="TEXT-ALIGN: center; MARGIN: 0cm 0cm 0pt" class=MsoNormal align=justify><SPAN lang=EN-US><?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /><o:p><SPAN style="FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt"><SPAN style="FONT-SIZE: 10pt"><SPAN lang=EN-US><o:p><SPAN style="FONT-SIZE: 12pt"><SPAN style="FONT-FAMILY: 宋体; FONT-SIZE: 12pt; mso-bidi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: ZH-CN; mso-bidi-language: AR-SA; mso-bidi-font-size: 9.0pt"><SPAN style="COLOR: #c71585"><SPAN style="FONT-FAMILY: 楷体_GB2312; COLOR: #c71585; FONT-SIZE: 18pt; mso-bidi-font-size: 9.0pt; mso-font-kerning: 0pt" lang=EN-US><SPAN style="COLOR: #c71585; FONT-SIZE: 18pt"><SPAN style="FONT-FAMILY: 楷体_GB2312; COLOR: #c71585; FONT-SIZE: 18pt; mso-hansi-font-family: 宋体; mso-bidi-font-size: 9.0pt; mso-font-kerning: 0pt" lang=EN-US><SPAN style="COLOR: #c71585"><SPAN style="FONT-FAMILY: 楷体_GB2312; COLOR: #c71585; FONT-SIZE: 18pt; mso-hansi-font-family: 宋体; mso-bidi-font-size: 9.0pt; mso-font-kerning: 0pt" lang=EN-US>1</SPAN><SPAN style="FONT-FAMILY: 楷体_GB2312; COLOR: #c71585; FONT-SIZE: 18pt; mso-hansi-font-family: 宋体; mso-bidi-font-size: 9.0pt; mso-font-kerning: 0pt">、着丝点蛋白通常有<SPAN style="COLOR: #c71585; FONT-SIZE: 18pt" lang=EN-US>4</SPAN>种：着丝点蛋白<SPAN style="COLOR: #c71585; FONT-SIZE: 18pt" lang=EN-US>A</SPAN>、<SPAN style="COLOR: #c71585; FONT-SIZE: 18pt" lang=EN-US>B</SPAN>、<SPAN style="COLOR: #c71585; FONT-SIZE: 18pt" lang=EN-US>C</SPAN>和<SPAN style="COLOR: #c71585; FONT-SIZE: 18pt" lang=EN-US>D</SPAN>，主要的靶抗原为着丝点蛋白<SPAN style="COLOR: #c71585; FONT-SIZE: 18pt" lang=EN-US>B</SPAN>，其能与含有各种着丝点抗体的血清发生反应。</SPAN><SPAN style="FONT-FAMILY: 楷体_GB2312; COLOR: #c71585; FONT-SIZE: 18pt; mso-bidi-font-size: 9.0pt; mso-font-kerning: 0pt" lang=EN-US><o:p></o:p></SPAN></SPAN></P>
<P style="BORDER-BOTTOM: windowtext; BORDER-LEFT: medium none; PADDING-BOTTOM: 0cm; MARGIN: 0cm 0cm 0pt; PADDING-LEFT: 0cm; LAYOUT-GRID-MODE: char; PADDING-RIGHT: 0cm; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0cm; tab-stops: center 207.65pt right 415.3pt; mso-element: para-border-div; mso-border-bottom-alt: solid windowtext .75pt; mso-padding-alt: 0cm 0cm 1.0pt 0cm; mso-layout-grid-align: none" class=MsoNormal align=justify><SPAN style="COLOR: #c71585"><SPAN style="FONT-FAMILY: 楷体_GB2312; COLOR: #c71585; FONT-SIZE: 18pt; mso-hansi-font-family: 宋体; mso-bidi-font-size: 9.0pt; mso-font-kerning: 0pt">刚抗体是系统性硬化亚型</SPAN><SPAN style="FONT-FAMILY: Times New Roman; COLOR: #c71585; FONT-SIZE: 18pt; mso-ascii-font-family: 楷体_GB2312; mso-fareast-font-family: 楷体_GB2312; mso-bidi-font-size: 9.0pt; mso-font-kerning: 0pt" lang=EN-US>———</SPAN><SPAN style="FONT-FAMILY: 楷体_GB2312; COLOR: #c71585; FONT-SIZE: 18pt; mso-hansi-font-family: 宋体; mso-bidi-font-size: 9.0pt; mso-font-kerning: 0pt" lang=EN-US>CREST</SPAN><SPAN style="FONT-FAMILY: 楷体_GB2312; COLOR: #c71585; FONT-SIZE: 18pt; mso-hansi-font-family: 宋体; mso-bidi-font-size: 9.0pt; mso-font-kerning: 0pt">综合征的特异性抗体，阳性率可达<SPAN style="COLOR: #c71585; FONT-SIZE: 18pt" lang=EN-US>80%-98%</SPAN>。</SPAN><SPAN style="FONT-FAMILY: 楷体_GB2312; COLOR: #c71585; FONT-SIZE: 18pt; mso-bidi-font-size: 9.0pt; mso-font-kerning: 0pt" lang=EN-US><o:p></o:p></SPAN></SPAN></P>
<P style="BORDER-BOTTOM: windowtext; BORDER-LEFT: medium none; PADDING-BOTTOM: 0cm; MARGIN: 0cm 0cm 0pt; PADDING-LEFT: 0cm; LAYOUT-GRID-MODE: char; PADDING-RIGHT: 0cm; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0cm; tab-stops: center 207.65pt right 415.3pt; mso-element: para-border-div; mso-border-bottom-alt: solid windowtext .75pt; mso-padding-alt: 0cm 0cm 1.0pt 0cm; mso-layout-grid-align: none" class=MsoNormal align=justify><SPAN style="COLOR: #c71585"><SPAN style="FONT-FAMILY: 楷体_GB2312; COLOR: #c71585; FONT-SIZE: 18pt; mso-hansi-font-family: 宋体; mso-bidi-font-size: 9.0pt; mso-font-kerning: 0pt" lang=EN-US>2</SPAN><SPAN style="FONT-FAMILY: 楷体_GB2312; COLOR: #c71585; FONT-SIZE: 18pt; mso-hansi-font-family: 宋体; mso-bidi-font-size: 9.0pt; mso-font-kerning: 0pt">、<SPAN style="COLOR: #c71585; FONT-SIZE: 18pt" lang=EN-US>CREST</SPAN>综合征患者较少涉及内脏损害，病情较轻，进展缓慢，病程较长。抗体阳性往往是患者预后较好的一个指标。</SPAN><SPAN style="FONT-FAMILY: 楷体_GB2312; COLOR: #c71585; FONT-SIZE: 18pt; mso-bidi-font-size: 9.0pt; mso-font-kerning: 0pt" lang=EN-US><o:p></o:p></SPAN></SPAN></P>
<P style="BORDER-BOTTOM: windowtext; BORDER-LEFT: medium none; PADDING-BOTTOM: 0cm; MARGIN: 0cm 0cm 0pt; PADDING-LEFT: 0cm; LAYOUT-GRID-MODE: char; PADDING-RIGHT: 0cm; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0cm; tab-stops: center 207.65pt right 415.3pt; mso-element: para-border-div; mso-border-bottom-alt: solid windowtext .75pt; mso-padding-alt: 0cm 0cm 1.0pt 0cm; mso-layout-grid-align: none" class=MsoNormal align=justify><SPAN style="COLOR: #c71585"><SPAN style="FONT-FAMILY: 楷体_GB2312; COLOR: #c71585; FONT-SIZE: 18pt; mso-hansi-font-family: 宋体; mso-bidi-font-size: 9.0pt; mso-font-kerning: 0pt" lang=EN-US>3</SPAN><SPAN style="FONT-FAMILY: 楷体_GB2312; COLOR: #c71585; FONT-SIZE: 18pt; mso-hansi-font-family: 宋体; mso-bidi-font-size: 9.0pt; mso-font-kerning: 0pt">、原发性雷诺现象患者（无其他<SPAN style="COLOR: #c71585; FONT-SIZE: 18pt" lang=EN-US>CREST</SPAN>症状或体征）中的阳性率为<SPAN style="COLOR: #c71585; FONT-SIZE: 18pt" lang=EN-US>25%</SPAN>，抗体阳性患者易发展成局限型系统性硬化。</SPAN><SPAN style="FONT-FAMILY: 楷体_GB2312; COLOR: #c71585; FONT-SIZE: 18pt; mso-bidi-font-size: 9.0pt; mso-font-kerning: 0pt" lang=EN-US><o:p></o:p></SPAN></SPAN></P>
<P style="BORDER-BOTTOM: windowtext; BORDER-LEFT: medium none; PADDING-BOTTOM: 0cm; MARGIN: 0cm 0cm 0pt; PADDING-LEFT: 0cm; LAYOUT-GRID-MODE: char; PADDING-RIGHT: 0cm; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0cm; tab-stops: center 207.65pt right 415.3pt; mso-element: para-border-div; mso-border-bottom-alt: solid windowtext .75pt; mso-padding-alt: 0cm 0cm 1.0pt 0cm; mso-layout-grid-align: none" class=MsoNormal align=justify><SPAN style="COLOR: #c71585"><SPAN style="FONT-FAMILY: 楷体_GB2312; COLOR: #c71585; FONT-SIZE: 18pt; mso-bidi-font-family: 'Times New Roman'; mso-hansi-font-family: 宋体; mso-ansi-language: EN-US; mso-fareast-language: ZH-CN; mso-bidi-language: AR-SA; mso-bidi-font-size: 9.0pt; mso-font-kerning: 0pt" lang=EN-US>4</SPAN><SPAN style="FONT-FAMILY: 楷体_GB2312; COLOR: #c71585; FONT-SIZE: 18pt; mso-bidi-font-family: 'Times New Roman'; mso-hansi-font-family: 宋体; mso-ansi-language: EN-US; mso-fareast-language: ZH-CN; mso-bidi-language: AR-SA; mso-bidi-font-size: 9.0pt; mso-font-kerning: 0pt">、抗着丝点抗体很少与抗<SPAN style="COLOR: #c71585; FONT-SIZE: 18pt" lang=EN-US>Scl-70</SPAN>抗体同时存在。</SPAN></SPAN></SPAN></SPAN></P></SPAN></SPAN>
<P style="MARGIN: 7.8pt 0cm" class=MsoNormal align=justify><SPAN style="FONT-FAMILY: 楷体_GB2312; FONT-SIZE: 12pt; mso-bidi-font-family: 'Times New Roman'; mso-hansi-font-family: 宋体; mso-ansi-language: EN-US; mso-fareast-language: ZH-CN; mso-bidi-language: AR-SA; mso-bidi-font-size: 9.0pt; mso-font-kerning: 0pt"></SPAN></SPAN></SPAN></o:p></SPAN></SPAN></SPAN></o:p></SPAN>&nbsp;</P>]]></description>
<author>华裕</author>
<pubDate>2010-6-28 11:41:00</pubDate>
</item>
<item>
<title><![CDATA[ANA（12）项的检测意义--抗Scl-70抗体]]></title>
<link>http://www.clinet.com.cn/blogu/109/archives/2010/4693.html</link>
<description><![CDATA[<SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 12pt"><SPAN style="FONT-FAMILY: Arial; COLOR: olivedrab; FONT-SIZE: 12pt; mso-hansi-font-family: 宋体; mso-bidi-font-size: 10.5pt; mso-font-kerning: 0pt" lang=EN-US>
<P style="MARGIN: 0cm 0cm 0pt; mso-pagination: widow-orphan" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; COLOR: olivedrab; FONT-SIZE: 12pt; mso-hansi-font-family: 宋体; mso-bidi-font-size: 10.5pt; mso-font-kerning: 0pt" lang=EN-US>1</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: olivedrab; FONT-SIZE: 12pt; mso-hansi-font-family: 宋体; mso-bidi-font-size: 10.5pt; mso-font-kerning: 0pt">、抗<SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 12pt" lang=EN-US>Scl-70</SPAN>抗体被视为系统性硬化的血清特异性抗体，局限性硬皮病患者此抗体一般为阴性，在其他结缔组织病和非结缔组织病极少阳性，因此，该抗体可称为系统性硬化的血清标记性抗体。</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: olivedrab; FONT-SIZE: 12pt; mso-bidi-font-family: 宋体; mso-bidi-font-size: 10.5pt; mso-font-kerning: 0pt" lang=EN-US><?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; COLOR: olivedrab; FONT-SIZE: 12pt; mso-hansi-font-family: 宋体; mso-bidi-font-size: 10.5pt; mso-font-kerning: 0pt" lang=EN-US><o:p>&nbsp;</o:p></SPAN></P>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; COLOR: olivedrab; FONT-SIZE: 12pt; mso-bidi-font-family: 宋体; mso-hansi-font-family: 宋体; mso-bidi-font-size: 10.5pt; mso-font-kerning: 0pt" lang=EN-US>2</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: olivedrab; FONT-SIZE: 12pt; mso-bidi-font-family: 宋体; mso-hansi-font-family: 宋体; mso-bidi-font-size: 10.5pt; mso-font-kerning: 0pt">、抗<SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 12pt" lang=EN-US>Scl-70</SPAN>抗体对诊断<SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 12pt" lang=EN-US>SSc</SPAN>的特异性为<SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 12pt" lang=EN-US>100%</SPAN>，敏感性为<SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 12pt" lang=EN-US>40%</SPAN>。<SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 12pt" lang=EN-US><o:p></o:p></SPAN></SPAN></P>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; COLOR: olivedrab; FONT-SIZE: 12pt; mso-bidi-font-family: 宋体; mso-hansi-font-family: 宋体; mso-bidi-font-size: 10.5pt; mso-font-kerning: 0pt" lang=EN-US><o:p>&nbsp;</o:p></SPAN></P>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; COLOR: olivedrab; FONT-SIZE: 12pt; mso-hansi-font-family: 宋体; mso-bidi-font-size: 10.5pt; mso-font-kerning: 0pt" lang=EN-US>3</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: olivedrab; FONT-SIZE: 12pt; mso-hansi-font-family: 宋体; mso-bidi-font-size: 10.5pt; mso-font-kerning: 0pt">、该抗体阳性与弥漫性皮肤病变、近端皮肤累及、肺间质纤维化、心脏受累、肾脏受累、远侧骨质溶解、指端凹陷性瘢痕、指（趾）关节畸形、并发肿瘤及神经系统受累密切相关，被视为预后不良的指标。</SPAN></SPAN></SPAN></P>]]></description>
<author>华裕</author>
<pubDate>2010-6-28 11:38:00</pubDate>
</item>
<item>
<title><![CDATA[ANA（12）项的检测意义--抗SSB/La抗体]]></title>
<link>http://www.clinet.com.cn/blogu/109/archives/2010/4692.html</link>
<description><![CDATA[<SPAN lang=EN-US><?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /><o:p><SPAN style="FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt">
<DIV align=justify><SPAN style="FONT-SIZE: 10pt"><SPAN lang=EN-US><o:p><SPAN style="FONT-SIZE: 12pt"><SPAN style="FONT-FAMILY: 宋体; FONT-SIZE: 12pt; mso-bidi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: ZH-CN; mso-bidi-language: AR-SA; mso-bidi-font-size: 9.0pt"><SPAN style="FONT-FAMILY: 楷体_GB2312; FONT-SIZE: 12pt; mso-bidi-font-family: 'Times New Roman'; mso-hansi-font-family: 宋体; mso-ansi-language: EN-US; mso-fareast-language: ZH-CN; mso-bidi-language: AR-SA; mso-bidi-font-size: 9.0pt; mso-font-kerning: 0pt">
<P style="TEXT-ALIGN: left; MARGIN: 7.8pt 0cm; mso-pagination: widow-orphan" class=MsoNormal align=left><SPAN style="COLOR: #6b8e23; FONT-SIZE: 14pt"><SPAN style="FONT-FAMILY: Modern; COLOR: #6b8e23; FONT-SIZE: 14pt; mso-hansi-font-family: 宋体; mso-bidi-font-size: 9.0pt; mso-font-kerning: 0pt" lang=EN-US>1</SPAN><SPAN style="FONT-FAMILY: Modern; COLOR: #6b8e23; FONT-SIZE: 14pt; mso-hansi-font-family: 宋体; mso-bidi-font-size: 9.0pt; mso-font-kerning: 0pt">、抗</SPAN><SPAN style="FONT-FAMILY: Modern; COLOR: #6b8e23; FONT-SIZE: 14pt; mso-hansi-font-family: 宋体; mso-font-kerning: 0pt" lang=EN-US>SSB</SPAN><SPAN style="FONT-FAMILY: Modern; COLOR: #6b8e23; FONT-SIZE: 14pt; mso-hansi-font-family: 宋体; mso-bidi-font-size: 9.0pt; mso-font-kerning: 0pt">抗体对诊断</SPAN><SPAN style="FONT-FAMILY: Modern; COLOR: #6b8e23; FONT-SIZE: 14pt; mso-hansi-font-family: 宋体; mso-font-kerning: 0pt" lang=EN-US>SS</SPAN><SPAN style="FONT-FAMILY: Modern; COLOR: #6b8e23; FONT-SIZE: 14pt; mso-hansi-font-family: 宋体; mso-bidi-font-size: 9.0pt; mso-font-kerning: 0pt">具有高度特异性，是</SPAN><SPAN style="FONT-FAMILY: Modern; COLOR: #6b8e23; FONT-SIZE: 14pt; mso-hansi-font-family: 宋体; mso-font-kerning: 0pt" lang=EN-US>SS</SPAN><SPAN style="FONT-FAMILY: Modern; COLOR: #6b8e23; FONT-SIZE: 14pt; mso-hansi-font-family: 宋体; mso-bidi-font-size: 9.0pt; mso-font-kerning: 0pt">的血清特异性抗体，原发性</SPAN><SPAN style="FONT-FAMILY: Modern; COLOR: #6b8e23; FONT-SIZE: 14pt; mso-hansi-font-family: 宋体; mso-font-kerning: 0pt" lang=EN-US>SS</SPAN><SPAN style="FONT-FAMILY: Modern; COLOR: #6b8e23; FONT-SIZE: 14pt; mso-hansi-font-family: 宋体; mso-bidi-font-size: 9.0pt; mso-font-kerning: 0pt">阳性率为</SPAN><SPAN style="FONT-FAMILY: Modern; COLOR: #6b8e23; FONT-SIZE: 14pt; mso-hansi-font-family: 宋体; mso-font-kerning: 0pt" lang=EN-US>65%-85%</SPAN><SPAN style="FONT-FAMILY: Modern; COLOR: #6b8e23; FONT-SIZE: 14pt; mso-hansi-font-family: 宋体; mso-bidi-font-size: 9.0pt; mso-font-kerning: 0pt">。抗</SPAN><SPAN style="FONT-FAMILY: Modern; COLOR: #6b8e23; FONT-SIZE: 14pt; mso-hansi-font-family: 宋体; mso-font-kerning: 0pt" lang=EN-US>SSA</SPAN><SPAN style="FONT-FAMILY: Modern; COLOR: #6b8e23; FONT-SIZE: 14pt; mso-hansi-font-family: 宋体; mso-bidi-font-size: 9.0pt; mso-font-kerning: 0pt">抗体和抗</SPAN><SPAN style="FONT-FAMILY: Modern; COLOR: #6b8e23; FONT-SIZE: 14pt; mso-hansi-font-family: 宋体; mso-font-kerning: 0pt" lang=EN-US>SSB</SPAN><SPAN style="FONT-FAMILY: Modern; COLOR: #6b8e23; FONT-SIZE: 14pt; mso-hansi-font-family: 宋体; mso-bidi-font-size: 9.0pt; mso-font-kerning: 0pt">抗体常同时出现，抗</SPAN><SPAN style="FONT-FAMILY: Modern; COLOR: #6b8e23; FONT-SIZE: 14pt; mso-hansi-font-family: 宋体; mso-font-kerning: 0pt" lang=EN-US>SSB</SPAN><SPAN style="FONT-FAMILY: Modern; COLOR: #6b8e23; FONT-SIZE: 14pt; mso-hansi-font-family: 宋体; mso-bidi-font-size: 9.0pt; mso-font-kerning: 0pt">抗体较抗</SPAN><SPAN style="FONT-FAMILY: Modern; COLOR: #6b8e23; FONT-SIZE: 14pt; mso-hansi-font-family: 宋体; mso-font-kerning: 0pt" lang=EN-US>SSA</SPAN><SPAN style="FONT-FAMILY: Modern; COLOR: #6b8e23; FONT-SIZE: 14pt; mso-hansi-font-family: 宋体; mso-bidi-font-size: 9.0pt; mso-font-kerning: 0pt">抗体诊断</SPAN><SPAN style="FONT-FAMILY: Modern; COLOR: #6b8e23; FONT-SIZE: 14pt; mso-hansi-font-family: 宋体; mso-font-kerning: 0pt" lang=EN-US>SS</SPAN><SPAN style="FONT-FAMILY: Modern; COLOR: #6b8e23; FONT-SIZE: 14pt; mso-hansi-font-family: 宋体; mso-bidi-font-size: 9.0pt; mso-font-kerning: 0pt">更为特异。</SPAN></SPAN></P>
<P style="TEXT-ALIGN: left; MARGIN: 7.8pt 0cm; mso-pagination: widow-orphan" class=MsoNormal align=left><SPAN style="COLOR: #6b8e23; FONT-SIZE: 14pt"><SPAN style="FONT-FAMILY: Modern; COLOR: #6b8e23; FONT-SIZE: 14pt; mso-hansi-font-family: 宋体; mso-bidi-font-size: 9.0pt; mso-font-kerning: 0pt"></SPAN><SPAN style="FONT-FAMILY: Modern; COLOR: #6b8e23; FONT-SIZE: 14pt; mso-bidi-font-family: 宋体; mso-font-kerning: 0pt" lang=EN-US><o:p></o:p></SPAN></SPAN>&nbsp;</P>
<P style="TEXT-ALIGN: left; MARGIN: 0cm 0cm 0pt" class=MsoNormal align=left><SPAN style="COLOR: #6b8e23; FONT-SIZE: 14pt"><SPAN style="FONT-FAMILY: Modern; COLOR: #6b8e23; FONT-SIZE: 14pt; mso-bidi-font-size: 9.0pt; mso-font-kerning: 0pt" lang=EN-US>2</SPAN><SPAN style="FONT-FAMILY: Modern; COLOR: #6b8e23; FONT-SIZE: 14pt; mso-hansi-font-family: 宋体; mso-bidi-font-size: 9.0pt; mso-font-kerning: 0pt">、同抗</SPAN><SPAN style="FONT-FAMILY: Modern; COLOR: #6b8e23; FONT-SIZE: 14pt; mso-hansi-font-family: 宋体; mso-font-kerning: 0pt" lang=EN-US>SSA</SPAN><SPAN style="FONT-FAMILY: Modern; COLOR: #6b8e23; FONT-SIZE: 14pt; mso-hansi-font-family: 宋体; mso-bidi-font-size: 9.0pt; mso-font-kerning: 0pt">抗体一样，抗</SPAN><SPAN style="FONT-FAMILY: Modern; COLOR: #6b8e23; FONT-SIZE: 14pt; mso-hansi-font-family: 宋体; mso-font-kerning: 0pt" lang=EN-US>SSB</SPAN><SPAN style="FONT-FAMILY: Modern; COLOR: #6b8e23; FONT-SIZE: 14pt; mso-hansi-font-family: 宋体; mso-bidi-font-size: 9.0pt; mso-font-kerning: 0pt">抗体亦可引起新生儿狼疮综合征（</SPAN><SPAN style="FONT-FAMILY: Modern; COLOR: #6b8e23; FONT-SIZE: 14pt; mso-hansi-font-family: 宋体; mso-font-kerning: 0pt" lang=EN-US>NLE</SPAN><SPAN style="FONT-FAMILY: Modern; COLOR: #6b8e23; FONT-SIZE: 14pt; mso-hansi-font-family: 宋体; mso-bidi-font-size: 9.0pt; mso-font-kerning: 0pt">），可造成先天性心脏传导阻滞。在其他自身免疫性疾病中如出现抗</SPAN><SPAN style="FONT-FAMILY: Modern; COLOR: #6b8e23; FONT-SIZE: 14pt; mso-hansi-font-family: 宋体; mso-font-kerning: 0pt" lang=EN-US>SSB</SPAN><SPAN style="FONT-FAMILY: Modern; COLOR: #6b8e23; FONT-SIZE: 14pt; mso-hansi-font-family: 宋体; mso-bidi-font-size: 9.0pt; mso-font-kerning: 0pt">抗体，患者常伴有继发性干燥综合征，唾液腺、唇腺活检可见大量淋巴细胞浸润。</SPAN></SPAN></P>
<P style="MARGIN: 7.8pt 0cm" class=MsoNormal></SPAN></SPAN></SPAN></o:p></SPAN></SPAN></SPAN></o:p></SPAN>&nbsp;</P></DIV>]]></description>
<author>华裕</author>
<pubDate>2010-6-28 11:35:00</pubDate>
</item>
<item>
<title><![CDATA[ANA（12）项的检测意义--抗SSA/Ro 60kd和52kd]]></title>
<link>http://www.clinet.com.cn/blogu/109/archives/2010/4691.html</link>
<description><![CDATA[<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt"><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt" lang=EN-US>1</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'">、抗</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt" lang=EN-US>SSA</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'">抗体主要见于原发性</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt" lang=EN-US>SS</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'">，阳性率达</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt" lang=EN-US>40</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'">％</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt" lang=EN-US>-95</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'">％，不同的检测方法对敏感性影响很大。也可见于</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt" lang=EN-US>SLE</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'">、</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt" lang=EN-US>RA</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'">、</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt" lang=EN-US>SSc</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'">、</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt" lang=EN-US>PBC</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'">等，偶见于慢性活动性肝炎（</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt" lang=EN-US>CAH</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'">）。</SPAN></SPAN></P>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt"><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'"></SPAN></SPAN>&nbsp;</P>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt"><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt" lang=EN-US>2</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'">、抗</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt" lang=EN-US>SSA</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'">抗体能直接参与组织的病理损害，特别是皮肤的损害，可引起亚急性皮肤型狼疮（</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt" lang=EN-US>SCLE</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'">）的皮损，抗体阳性率</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt" lang=EN-US>70%-90%</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'">。</SPAN></SPAN></P>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt"><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt" lang=EN-US>3</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'">、</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt" lang=EN-US>IgG</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'">类抗体通过胎盘进入胎儿后，可引起新生儿狼疮综合征（</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt" lang=EN-US>NLE</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'">），抗体的阳性率大于</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt" lang=EN-US>90%</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'">，与胎儿的心脏传导系统结合，可造成先天性心脏传导阻滞。</SPAN></SPAN></P>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt" lang=EN-US><?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /><o:p><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt">&nbsp;</SPAN></o:p></SPAN></P>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt"><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt" lang=EN-US>3</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'">、抗</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt" lang=EN-US>SSA</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'">两种蛋白质（</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt" lang=EN-US>52000</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'">和</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt" lang=EN-US>60000</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'">）的抗体均可见于</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt" lang=EN-US>SS</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'">及</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt" lang=EN-US>SLE</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'">。但单独出现抗</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt" lang=EN-US>52000</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'">抗体更多见于</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt" lang=EN-US>SS</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'">中，而只出现抗</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt" lang=EN-US>60000</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'">抗体，则更多见于</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt" lang=EN-US>SLE</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'">，尤其是亚急性皮肤型狼疮（</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt" lang=EN-US>SCLE</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'">）。</SPAN></SPAN></P>
<P><SPAN style="COLOR: #6b8e23"></SPAN>&nbsp;</P>]]></description>
<author>华裕</author>
<pubDate>2010-6-28 11:25:00</pubDate>
</item>
<item>
<title><![CDATA[ANA（12）项的检测意义---U1-snRNP]]></title>
<link>http://www.clinet.com.cn/blogu/109/archives/2010/4660.html</link>
<description><![CDATA[<SPAN style="COLOR: #6b8e23" lang=EN-US><?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /><o:p><SPAN style="FONT-FAMILY: Times New Roman; COLOR: #6b8e23; FONT-SIZE: 12pt">
<DIV align=justify>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="COLOR: #6b8e23"><SPAN style="COLOR: #6b8e23; mso-hansi-font-family: Arial" lang=EN-US>1.</SPAN><SPAN style="FONT-FAMILY: 宋体; COLOR: #6b8e23; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'">抗</SPAN><SPAN style="COLOR: #6b8e23; mso-hansi-font-family: Arial" lang=EN-US>U1RNP</SPAN><SPAN style="FONT-FAMILY: 宋体; COLOR: #6b8e23; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'">抗体在混合性结缔组织病（</SPAN><SPAN style="COLOR: #6b8e23; mso-hansi-font-family: Arial" lang=EN-US>MCTD</SPAN><SPAN style="FONT-FAMILY: 宋体; COLOR: #6b8e23; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'">）患者中阳性率最高，几乎见于所有的</SPAN><SPAN style="COLOR: #6b8e23; mso-hansi-font-family: Arial" lang=EN-US>MCTD</SPAN><SPAN style="FONT-FAMILY: 宋体; COLOR: #6b8e23; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'">患者，阳性率＞</SPAN><SPAN style="COLOR: #6b8e23; mso-hansi-font-family: Arial" lang=EN-US>95</SPAN><SPAN style="FONT-FAMILY: 宋体; COLOR: #6b8e23; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'">％。出现高滴度的抗</SPAN><SPAN style="COLOR: #6b8e23; mso-hansi-font-family: Arial" lang=EN-US>U1RNP</SPAN><SPAN style="FONT-FAMILY: 宋体; COLOR: #6b8e23; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'">抗体，且无其他特异性的抗核抗体，是诊断</SPAN><SPAN style="COLOR: #6b8e23; mso-hansi-font-family: Arial" lang=EN-US>MCTD</SPAN><SPAN style="FONT-FAMILY: 宋体; COLOR: #6b8e23; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'">的重要血清学依据。</SPAN></SPAN></P>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="COLOR: #6b8e23"><SPAN style="FONT-FAMILY: 宋体; COLOR: #6b8e23; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'"></SPAN><SPAN style="COLOR: #6b8e23; mso-hansi-font-family: Arial" lang=EN-US><o:p>抗U1核糖核蛋白抗体（U1-snRNP）</o:p></SPAN></SPAN></P>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="COLOR: #6b8e23"><SPAN style="COLOR: #6b8e23; mso-hansi-font-family: Arial" lang=EN-US><o:p></o:p></SPAN></SPAN>&nbsp;</P>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="COLOR: #6b8e23"><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23" lang=EN-US>2</SPAN><SPAN style="FONT-FAMILY: 宋体; COLOR: #6b8e23; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial">、抗</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23" lang=EN-US>U1RNP</SPAN><SPAN style="FONT-FAMILY: 宋体; COLOR: #6b8e23; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial">抗体虽然为混合结缔组织病较特异性的抗体，但此抗体在</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23" lang=EN-US>SLE</SPAN><SPAN style="FONT-FAMILY: 宋体; COLOR: #6b8e23; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial">中出现率也可以达到</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23" lang=EN-US>30</SPAN><SPAN style="FONT-FAMILY: 宋体; COLOR: #6b8e23; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial">％～</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23" lang=EN-US>40</SPAN><SPAN style="FONT-FAMILY: 宋体; COLOR: #6b8e23; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial">％，并且可伴有</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23" lang=EN-US>Sm</SPAN><SPAN style="FONT-FAMILY: 宋体; COLOR: #6b8e23; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial">抗体的出现或单独出现。</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23" lang=EN-US>SLE</SPAN><SPAN style="FONT-FAMILY: 宋体; COLOR: #6b8e23; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial">患者出现抗</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23" lang=EN-US>U1RNP</SPAN><SPAN style="FONT-FAMILY: 宋体; COLOR: #6b8e23; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial">抗体与临床表现及实验室指标有一定关系，如果</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23" lang=EN-US>SLE</SPAN><SPAN style="FONT-FAMILY: 宋体; COLOR: #6b8e23; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial">患者出现抗</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23" lang=EN-US>U1RNP</SPAN><SPAN style="FONT-FAMILY: 宋体; COLOR: #6b8e23; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial">抗体，应提示患者注意关节及肢端的变化，而且抗</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23" lang=EN-US>U1RNP</SPAN><SPAN style="FONT-FAMILY: 宋体; COLOR: #6b8e23; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial">抗体阳性患者有更多的自身抗体同时出现提示疾病的活动性较大，但这并不一定说明病情严重，病情严重程度的评估还要结合临床。</SPAN></SPAN></P>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="COLOR: #6b8e23"><SPAN style="FONT-FAMILY: 宋体; COLOR: #6b8e23; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial"></SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23" lang=EN-US><o:p></o:p></SPAN></SPAN>&nbsp;</P>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="COLOR: #6b8e23"><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23" lang=EN-US>3</SPAN><SPAN style="FONT-FAMILY: 宋体; COLOR: #6b8e23; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial">、在抗</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23" lang=EN-US>U1RNP</SPAN><SPAN style="FONT-FAMILY: 宋体; COLOR: #6b8e23; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial">抗体阳性的</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23" lang=EN-US>MCTD</SPAN><SPAN style="FONT-FAMILY: 宋体; COLOR: #6b8e23; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial">或</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23" lang=EN-US>SLE</SPAN><SPAN style="FONT-FAMILY: 宋体; COLOR: #6b8e23; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial">患者中，常与肌炎、食道蠕动功能低下、雷诺现象、关节痛、指硬化和肺脏的间质性改变等临床症状密切相关，且此抗体阳性的患者其肾炎的发病率极低。</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23" lang=EN-US>&nbsp;<o:p></o:p></SPAN></SPAN></P></SPAN></o:p></SPAN></DIV>]]></description>
<author>华裕</author>
<pubDate>2010-6-23 9:18:00</pubDate>
</item>
<item>
<title><![CDATA[ANA（12）项的检测意义-----抗组蛋白（Histone）抗体]]></title>
<link>http://www.clinet.com.cn/blogu/109/archives/2010/4659.html</link>
<description><![CDATA[<SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt; mso-hansi-font-family: Calibri; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 宋体; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-latin">
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23"><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23" lang=EN-US>1</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial">、抗组蛋白抗体可以在多种结缔组织病中出现，不具有诊断特异性，例如，在</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23" lang=EN-US>SLE</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial">患者中的阳性率为</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23" lang=EN-US>30%-80%</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial">，药物性狼疮的阳性率可高达</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23" lang=EN-US>90%</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial">以上。</SPAN></SPAN></P>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23"><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial"></SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23" lang=EN-US><?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></SPAN>&nbsp;</P>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23"><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23" lang=EN-US>2</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial">、抗组蛋白抗体在药物性狼疮</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23" lang=EN-US>DIL</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial">患者中阳性率较高，如仅有抗组蛋白抗体抗体而不伴有其他</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23" lang=EN-US>ANA</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial">，则强烈支持</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23" lang=EN-US>DIL</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial">诊断。</SPAN></SPAN></P>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23"><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial"></SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23" lang=EN-US><o:p></o:p></SPAN></SPAN>&nbsp;</P>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23"><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23" lang=EN-US>3</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial">、抗组蛋白抗体阳性的</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23" lang=EN-US>SLE</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial">患者临床上伴有肾炎者多见，中枢神经系统受累者则较少见。</SPAN></SPAN></SPAN></P>]]></description>
<author>华裕</author>
<pubDate>2010-6-23 9:13:00</pubDate>
</item>
<item>
<title><![CDATA[ANA（12）项的检测意义-----抗核糖体P0蛋白抗体]]></title>
<link>http://www.clinet.com.cn/blogu/109/archives/2010/4658.html</link>
<description><![CDATA[<SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 12pt" lang=EN-US><?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /><o:p><SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 12pt">
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; COLOR: #4b0082; FONT-SIZE: 12pt"></SPAN>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; COLOR: #4b0082; FONT-SIZE: 12pt"><SPAN style="FONT-FAMILY: Arial; COLOR: #4b0082; FONT-SIZE: 12pt; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'"></SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #4b0082; FONT-SIZE: 12pt" lang=EN-US><o:p></o:p></SPAN></SPAN></P>
<DIV align=justify>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt"><SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 12pt" lang=EN-US><STRONG>抗核糖体（rRNP）P0蛋白抗体</STRONG></SPAN></SPAN></P>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt"><SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 12pt" lang=EN-US></SPAN></SPAN>&nbsp;</P>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt"><SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 12pt" lang=EN-US>1</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial">、抗</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt" lang=EN-US>rRNP</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial">抗体的靶抗原为细胞质中</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt" lang=EN-US>60S</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial">核糖体大亚基上</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt" lang=EN-US>P0</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial">、</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt" lang=EN-US>P1</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial">和</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt" lang=EN-US>P2</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial">，</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt" lang=EN-US>3</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial">个磷酸化蛋白。</SPAN></SPAN></P>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt"><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial"></SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt" lang=EN-US><o:p></o:p></SPAN></SPAN>&nbsp;</P>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt"><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt" lang=EN-US>2</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial">、抗</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt" lang=EN-US>rRNP</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial">抗体为</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt" lang=EN-US>SLE</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial">的血清高度特异性抗体，阳性率在</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt" lang=EN-US>10%</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial">～</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt" lang=EN-US>40%</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial">。</SPAN></SPAN></P>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt"><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial"></SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt" lang=EN-US><o:p></o:p></SPAN></SPAN>&nbsp;</P>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt"><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt" lang=EN-US>3</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial">、</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt" lang=EN-US>SLE</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial">患者出现抗</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt" lang=EN-US>rRNP</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial">抗体与中枢神经系统、肝脏或肾脏受累相关。抗</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt" lang=EN-US>rRNP</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial">抗体常在</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt" lang=EN-US>SLE</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial">活动期存在，有时并不会随病情的缓解立即消失，可持续</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt" lang=EN-US>1</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial">～</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt" lang=EN-US>2</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial">年后才转为阴性。</SPAN></SPAN></P>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt"><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial"></SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt" lang=EN-US><o:p></o:p></SPAN></SPAN>&nbsp;</P>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt"><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt" lang=EN-US>4</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial">、抗</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt" lang=EN-US>rRNP</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial">抗体更多出现在有严重精神病表现，特别是抑郁症的狼疮患者中。虽然文献中对此有争论，但在行为异常发作时，抗</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt" lang=EN-US>rRNP</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial">抗体滴度的升高对狼疮精神病（狼疮脑病）的诊断有一定提示作用。具有脑炎和精神病症状的</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt" lang=EN-US>SLE</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial">患者，抗</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt" lang=EN-US>rRNP</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial">抗体的敏感性为</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt" lang=EN-US>56%-90%</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 12pt; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial">。</SPAN></SPAN></P></SPAN></o:p></SPAN></DIV>]]></description>
<author>华裕</author>
<pubDate>2010-6-23 9:09:00</pubDate>
</item>
<item>
<title><![CDATA[ANA（12）项的检测意义-----抗SmD1抗体]]></title>
<link>http://www.clinet.com.cn/blogu/109/archives/2010/4657.html</link>
<description><![CDATA[<SPAN style="COLOR: #6b8e23" lang=EN-US><?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /><o:p><SPAN style="FONT-FAMILY: Times New Roman; COLOR: #6b8e23; FONT-SIZE: 12pt">
<DIV align=justify><SPAN style="FONT-FAMILY: 宋体; COLOR: #6b8e23">
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="COLOR: #6b8e23"><SPAN style="FONT-FAMILY: Times New Roman; COLOR: #6b8e23" lang=EN-US>1</SPAN><SPAN style="FONT-FAMILY: 宋体; COLOR: #6b8e23; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'">、抗</SPAN><SPAN style="FONT-FAMILY: Times New Roman; COLOR: #6b8e23" lang=EN-US>SmD1</SPAN><SPAN style="FONT-FAMILY: 宋体; COLOR: #6b8e23; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'">抗体是</SPAN><SPAN style="FONT-FAMILY: Times New Roman; COLOR: #6b8e23" lang=EN-US>SLE</SPAN><SPAN style="FONT-FAMILY: 宋体; COLOR: #6b8e23; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'">的特异性自身抗体，其特异性和敏感性均较高，特异性达</SPAN><SPAN style="FONT-FAMILY: Times New Roman; COLOR: #6b8e23" lang=EN-US>97.1%</SPAN><SPAN style="FONT-FAMILY: 宋体; COLOR: #6b8e23; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'">。</SPAN></SPAN></P>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="COLOR: #6b8e23" lang=EN-US><o:p><SPAN style="FONT-FAMILY: Times New Roman; COLOR: #6b8e23">&nbsp;</SPAN></o:p></SPAN></P>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="COLOR: #6b8e23"><SPAN style="FONT-FAMILY: Times New Roman; COLOR: #6b8e23" lang=EN-US>2</SPAN><SPAN style="FONT-FAMILY: 宋体; COLOR: #6b8e23; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'">、抗</SPAN><SPAN style="FONT-FAMILY: Times New Roman; COLOR: #6b8e23" lang=EN-US>Sm</SPAN><SPAN style="FONT-FAMILY: 宋体; COLOR: #6b8e23; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'">抗体阴性</SPAN><SPAN style="FONT-FAMILY: Times New Roman; COLOR: #6b8e23" lang=EN-US>SLE</SPAN><SPAN style="FONT-FAMILY: 宋体; COLOR: #6b8e23; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'">患者中可检测到</SPAN><SPAN style="FONT-FAMILY: Times New Roman; COLOR: #6b8e23" lang=EN-US>SmD1</SPAN><SPAN style="FONT-FAMILY: 宋体; COLOR: #6b8e23; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'">抗体，而在</SPAN><SPAN style="FONT-FAMILY: Times New Roman; COLOR: #6b8e23" lang=EN-US>SmD1</SPAN><SPAN style="FONT-FAMILY: 宋体; COLOR: #6b8e23; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'">抗体阴性</SPAN><SPAN style="FONT-FAMILY: Times New Roman; COLOR: #6b8e23" lang=EN-US>SLE</SPAN><SPAN style="FONT-FAMILY: 宋体; COLOR: #6b8e23; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'">患者中未能检测到</SPAN><SPAN style="FONT-FAMILY: Times New Roman; COLOR: #6b8e23" lang=EN-US>Sm</SPAN><SPAN style="FONT-FAMILY: 宋体; COLOR: #6b8e23; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'">抗体，显示</SPAN><SPAN style="FONT-FAMILY: Times New Roman; COLOR: #6b8e23" lang=EN-US>SmD1</SPAN><SPAN style="FONT-FAMILY: 宋体; COLOR: #6b8e23; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'">抗体敏感性高于</SPAN><SPAN style="FONT-FAMILY: Times New Roman; COLOR: #6b8e23" lang=EN-US>Sm</SPAN><SPAN style="FONT-FAMILY: 宋体; COLOR: #6b8e23; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'">抗体。</SPAN></SPAN></P>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="COLOR: #6b8e23" lang=EN-US><o:p><SPAN style="FONT-FAMILY: Times New Roman; COLOR: #6b8e23">&nbsp;</SPAN></o:p></SPAN></P></SPAN></SPAN></o:p></SPAN></DIV>]]></description>
<author>华裕</author>
<pubDate>2010-6-23 9:04:00</pubDate>
</item>
<item>
<title><![CDATA[ANA（12）项的检测意义----抗核小体抗体]]></title>
<link>http://www.clinet.com.cn/blogu/109/archives/2010/4656.html</link>
<description><![CDATA[<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 14pt"><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 14pt" lang=EN-US><STRONG>抗核小体（Nucleosome）抗体</STRONG></SPAN></SPAN></P>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 14pt"><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 14pt" lang=EN-US></SPAN></SPAN>&nbsp;</P>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 14pt"><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 14pt" lang=EN-US>1</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 14pt; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'">、</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 14pt" lang=EN-US>ANuA</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 14pt; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'">近年来认为是</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 14pt" lang=EN-US>SLE</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 14pt; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'">血清学标志而且敏感性高。</SPAN></SPAN></P>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 14pt"><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 14pt; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'"></SPAN></SPAN>&nbsp;</P>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 14pt"><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 14pt" lang=EN-US>2</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 14pt; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'">、</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 14pt" lang=EN-US>AnuA</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 14pt; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'">可在抗</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 14pt" lang=EN-US>dsDNA</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 14pt; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'">抗体阴性和抗</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 14pt" lang=EN-US>Sm</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 14pt; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'">阴性的</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 14pt" lang=EN-US>SLE</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 14pt; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'">患者中有很高的阳性率，</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 14pt" lang=EN-US>AnuA</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 14pt; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'">的检测能提高</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 14pt" lang=EN-US>SLE</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 14pt; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'">诊断的敏感性。</SPAN></SPAN></P>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 14pt"><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 14pt; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'"></SPAN></SPAN>&nbsp;</P>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 14pt"><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 14pt" lang=EN-US>3</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 14pt; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'">、</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 14pt" lang=EN-US>AnuA</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 14pt; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'">与抗</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 14pt" lang=EN-US>Sm</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 14pt; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'">和</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 14pt" lang=EN-US>dsDNA</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 14pt; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'">联合检测较单一抗体检测</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 14pt" lang=EN-US>SLE</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 14pt; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'">的敏感性高，可弥补单一抗体检测的不足。</SPAN></SPAN></P>]]></description>
<author>华裕</author>
<pubDate>2010-6-23 9:00:00</pubDate>
</item>
<item>
<title><![CDATA[ANA（12）项的检测意义----抗dsDNA抗体]]></title>
<link>http://www.clinet.com.cn/blogu/109/archives/2010/4655.html</link>
<description><![CDATA[<SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 14pt" lang=EN-US><?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /><o:p><SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 14pt"><SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 14pt"><SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 14pt" lang=EN-US><o:p><SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 14pt">
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 14pt"><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 14pt" lang=EN-US>1</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 14pt; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'">、抗</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 14pt" lang=EN-US>dsDNA</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 14pt; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'">抗体是</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 14pt" lang=EN-US>SLE</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 14pt; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'">患者的特征性标志抗体。</SPAN></SPAN></P>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 14pt; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'"></SPAN>&nbsp;</P>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 14pt"><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 14pt" lang=EN-US>2</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 14pt; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'">、</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 14pt" lang=EN-US>70</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 14pt; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'">％</SPAN> <SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 14pt; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'">～</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 14pt" lang=EN-US>90</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 14pt; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'">％的活动期</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 14pt" lang=EN-US>SLE</SPAN><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 14pt; mso-hansi-font-family: 'Times New Roman'; mso-ascii-font-family: 'Times New Roman'">病人该抗体阳性，其抗体的滴度与疾病的活动程度有相关性，但其敏感性较低。</SPAN></SPAN></P>
<P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; COLOR: #6b8e23; FONT-SIZE: 14pt" lang=EN-US><o:p>&nbsp;</o:p></SPAN></P>
<P style="TEXT-ALIGN: center; MARGIN: 0cm 0cm 0pt" class=MsoNormal align=center><SPAN style="FONT-SIZE: 14pt"></SPAN></P></SPAN></o:p></SPAN></SPAN></SPAN></o:p></SPAN>]]></description>
<author>华裕</author>
<pubDate>2010-6-23 8:54:00</pubDate>
</item>
<item>
<title><![CDATA[治疗类风湿关节炎的标志物——RA33]]></title>
<link>http://www.clinet.com.cn/blogu/109/archives/2010/4649.html</link>
<description><![CDATA[<P style="WORD-BREAK: break-all" align=justify><SPAN style="FONT-FAMILY: 宋体; FONT-SIZE: 12pt; mso-hansi-font-family: Calibri; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 宋体; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-latin"><SPAN style="FONT-FAMILY: 宋体; COLOR: #7030a0; mso-hansi-font-family: Calibri; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 宋体; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-latin"><SPAN style="FONT-FAMILY: 宋体; COLOR: #7030a0; mso-hansi-font-family: Calibri; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 宋体; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-latin"><SPAN style="FONT-FAMILY: 宋体; COLOR: #7030a0; mso-hansi-font-family: Calibri; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 宋体; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-latin"><SPAN style="FONT-FAMILY: Arial; COLOR: #4682b4; FONT-SIZE: 12pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; RA33作为多相核蛋白A2/B1所为人熟知，是一种人类自身免疫性疾病中的自身抗原。<?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P>
<P style="TEXT-ALIGN: left; TEXT-INDENT: 24.1pt; MARGIN: 7.8pt 0cm; mso-char-indent-count: 2.0; mso-pagination: widow-orphan" class=MsoNormal align=justify><SPAN style="FONT-FAMILY: Arial; COLOR: #4682b4; FONT-SIZE: 12pt">在1989年，RA病人血清中的一种新的自身抗体被发现，是一种Hela细胞核提取物中的分子量大约33kD的蛋白质。因此将此抗原取名RA33。将高纯度的RA33进行蛋白序列分析，发现其与多相核蛋白A2/B1是完全相同的。抗RA33抗体出现在约30-35%的RA患者中，20-25%的SLE患者中和35-40%的混合型结缔组织病（MCTD）患者中。对于非自身免疫性的关节炎性疾病抗RA33很少阳性。<o:p></o:p></SPAN></P>
<P style="TEXT-ALIGN: left; TEXT-INDENT: 24.1pt; MARGIN: 7.8pt 0cm; mso-char-indent-count: 2.0; mso-pagination: widow-orphan" class=MsoNormal align=justify><SPAN style="FONT-FAMILY: Arial; COLOR: #4682b4; FONT-SIZE: 12pt">常规检测抗RA33一般使用ELISA法。间接免疫荧光法对于检测RA33是受限的。值得注意的是，抗RA33抗体在RA发病的最早期即能检测到，甚至在临床出现表现之前的几年内就能检测到。RA33阳性预测率为74%。<o:p></o:p></SPAN></P>
<P style="TEXT-ALIGN: left; TEXT-INDENT: 24.1pt; MARGIN: 7.8pt 0cm; mso-char-indent-count: 2.0; mso-pagination: widow-orphan" class=MsoNormal align=justify><SPAN style="FONT-FAMILY: Arial; COLOR: #4682b4; FONT-SIZE: 12pt">出于增加诊断敏感性的目的以及在遇到血清检测阴性的RA患者时，可在开始时就进行RA33抗体检测或者在RF和抗CCP均为阴性时检测RA33抗体。</SPAN><STRONG>&nbsp;<SPAN style="FONT-FAMILY: 宋体; COLOR: #7030a0; mso-hansi-font-family: Calibri; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 宋体; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-latin"><SPAN style="FONT-FAMILY: 宋体; COLOR: #7030a0; mso-hansi-font-family: Calibri; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 宋体; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-latin"></P></SPAN></SPAN></STRONG></SPAN></SPAN></SPAN></SPAN>]]></description>
<author>华裕</author>
<pubDate>2010-6-22 9:15:00</pubDate>
</item>
<item>
<title><![CDATA[类风湿关节炎介绍]]></title>
<link>http://www.clinet.com.cn/blogu/109/archives/2010/4648.html</link>
<description><![CDATA[<DIV align=justify>
<P style="TEXT-JUSTIFY: inter-ideograph; TEXT-ALIGN: justify; MARGIN: auto 0cm" class=MsoNormal><SPAN style="FONT-FAMILY: 宋体; COLOR: #8b4513; FONT-SIZE: 12pt">&nbsp;&nbsp;&nbsp; <SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 12pt">治疗类风关早期开始用药效果最好。然而在疾病初期大多数诊断标准是不完善的。三种独立的指标：类风湿因子（<SPAN style="FONT-FAMILY: Arial; COLOR: #8b4513; FONT-SIZE: 12pt" lang=EN-US>RF</SPAN>）、抗<SPAN style="FONT-FAMILY: Arial; COLOR: #8b4513; FONT-SIZE: 12pt" lang=EN-US>CCP</SPAN>抗体、抗<SPAN style="FONT-FAMILY: Arial; COLOR: #8b4513; FONT-SIZE: 12pt" lang=EN-US>RA33</SPAN>抗体，联合进行检测可增强诊断类风湿关节炎的敏感性，因此在诊断早期类风湿关节炎方面表现最好。</SPAN></SPAN></P>
<P style="TEXT-JUSTIFY: inter-ideograph; TEXT-ALIGN: justify; MARGIN: auto 0cm" class=MsoNormal><SPAN style="FONT-FAMILY: Arial; COLOR: #8b4513; FONT-SIZE: 12pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;类风湿关节炎是一种慢性的、系统性的炎性疾病，其可以影响很多组织和器官，但是主要产生关节膜炎攻击关节接合部位，经常导致关节软骨的破坏和关节强直。类风湿关节炎还会将炎症漫射到肺部、心包膜、胸膜和巩膜，以及产生瘤性损害，最主要是在皮下组织。虽然类风湿关节炎的起病原因还是未知的，但是从长期性和进展性的特点可见自身免疫起到关键的作用。</SPAN></P><SPAN style="FONT-FAMILY: Arial; COLOR: #8b4513; FONT-SIZE: 12pt; mso-bidi-font-family: 宋体; mso-ansi-language: EN-US; mso-fareast-language: ZH-CN; mso-bidi-language: AR-SA">&nbsp;&nbsp; 全球将近<SPAN style="FONT-FAMILY: Arial; COLOR: #8b4513; FONT-SIZE: 12pt" lang=EN-US>2%</SPAN>的人口正饱受着类风湿关节炎带来的痛苦，其中女性患者是男性患者的三倍左右。通常在<SPAN style="FONT-FAMILY: Arial; COLOR: #8b4513; FONT-SIZE: 12pt" lang=EN-US>40-50</SPAN>岁左右发病，但是所有年纪都不是免疫的。此病痛苦可致残，能够导致功能和活动性的丧失。主要依靠临床征状和表现进行诊断，但是最主要地依靠血液检测（特别是检测<SPAN style="FONT-FAMILY: Arial; COLOR: #8b4513; FONT-SIZE: 12pt" lang=EN-US>RF</SPAN>、抗<SPAN style="FONT-FAMILY: Arial; COLOR: #8b4513; FONT-SIZE: 12pt" lang=EN-US>CCP</SPAN>和现在的抗<SPAN style="FONT-FAMILY: Arial; COLOR: #8b4513; FONT-SIZE: 12pt" lang=EN-US>RA33</SPAN>）和<SPAN style="FONT-FAMILY: Arial; COLOR: #8b4513; FONT-SIZE: 12pt" lang=EN-US>X</SPAN>光<SPAN style="FONT-FAMILY: Arial; COLOR: #8b4513; FONT-SIZE: 12pt; mso-bidi-font-family: 宋体; mso-ansi-language: EN-US; mso-fareast-language: ZH-CN; mso-bidi-language: AR-SA">检测。</SPAN></SPAN></DIV>]]></description>
<author>华裕</author>
<pubDate>2010-6-22 9:10:00</pubDate>
</item>

</channel>
</rss>